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Dedication 
 
To All Children and Adolescents Living with HIV/AIDS in the World 
 
My earnest desire is to see this work make a change in your well-being. 
You deserve to grow and achieve your full potential in life. 
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ABSTRACT    
 
Background: Identification of children and adolescents living with HIV/AIDS remains a 
major challenge to the expansion of antiretroviral therapy among this subpopulation. This 
study assesses and compares the acceptability, feasibility and effectiveness of the 
targeted and the blanket provider-initiated-testing and counselling (PITC) for HIV among 
children and adolescents in Cameroon. 
Methods: During a 6-month period, we invited in 3 hospitals in Cameroon, HIV positive 
parents to have their biological children (6 weeks-19 years) tested for HIV (targeted 
PITC or tPITC). During that same period and in the same hospitals, we routinely offered 
HIV testing to all sick children seen at outpatient consultations (blanket PITC or bPITC). 
Children of consenting parents were enrolled and HIV tested according to the national 
guidelines. The study outcomes were assessed and compared using descriptive and 
inferential statistics at 5% significant level.  
Results: We enrolled 1240 and 2459 eligible parents respectively in the tPITC and bPITC 
group and among them and in the same order 99.7% (1236/1240) and 98.8% (2430/2459) 
accepted to have their children tested for HIV.   Through these parents, 4719 children 
including 1990 in the tPITC and 2729 in the bPITC group were eligible for HIV testing and 
in the same order, 56.7% (1129/1990) and 90.3% (2465/2729) of them were finally tested 
for HIV (p<0. 0001). The HIV case detection among children was 3.5% (95%CI: 2.3-4.4) 
versus 1.6% (95%CI: 1.1-2.1) (p=0.0008, RR=2.1) respectively in tPITC and bPITC group 
and to identify one new case, 29 and 62 children have to be tested in the same order.   
Conclusion:  The HIV testing acceptance for children was high among parents  with both 
strategies and the HIV case detection was twice as high with tPITC as with bPITC.   
However, the low HIV testing uptake renders tPITC less feasible and addressing this 
challenge is required for the optimal outcome of this higher yield approach.  
 
 Key words: Identification, HIV, pediatric, adolescents, targeted PITC, blanket PITC 
Registration: Clinicaltrials.gov #:  NCT03024762 
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I.1. Background 
According to UNAIDS, 36.9 million [34.3 million–41.4million] people were living 
with HIV/AIDS in the world in 2014 and among this number, 15,8 million were on ART (1)  
indicating that the world was ahead of time in reaching the 15 million by 2015 target set 
by the United Nations General Assembly in 2011(2) . However, despite this significant 
achievement in meeting the global ART target, HIV infected children under the age of 15 
years had a significantly lower ART coverage   as only 32% [30%-34%] of children eligible 
were on treatment against 41% [38%-46%] of adults (1).  
Cameroon is a country in Central Africa, bordered by Nigeria to the west; Chad to 
the northeast; the Central African Republic to the east; and the Republic of the Congo 
and Gabon to the south. This country covers an area of 475 650 square kilometers and 
has a population of 19 406 100 inhabitants (3). French and English are the country’s 
official languages, with French being the predominant language. The population of 
Cameroon is young with 44% being under 15 years old.  The population is growing at a 
rate of 2.6% and life expectancy at birth was approximately 55.93 years in 2015. The 
health system is organized into three levels: the operational/service delivery level, 
corresponding to the district health services; the intermediate level (regional delegations), 
responsible for technical support; and the central level (ministry of health), responsible 
for health policy/development strategies. The health system still suffers from weak 
governance system, a quantitative and qualitative shortage of human resources, 
insufficient technical and managerial expertise and weak health information system (4). 
This country has a generalized HIV/AIDS epidemic with a prevalence of 4,3% in the 
general population (5). In 2014, pediatric ART coverage in this country was 10.4 % as 
against 28% in adults (6). This shows that the gap in pediatric ART coverage in Cameroon 
is even wider and points out the need for a new dynamic to identify HIV infected children 
and enroll them into care in order to fast track universal coverage of HIV care and 
treatment among children in this country.   
  In 2011, the international community adopted the Global Plan towards achieving 
an AIDS-free generation by 2015, meaning a generation in which all children are born 
free of HIV and those already infected have access to treatment, care and support they 
need to remain alive and well (7). This implies that achieving an AIDS-free generation 
requires an adequate coverage of mother to child transmission (MTCT) services targeting 
both prevention of new infections among children and treatment of those living with 
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HIV/AIDS.  Worldwide, 73% [68%-79%] of pregnant women living with HIV had access to 
antiretroviral medicines to prevent transmission of HIV to their babies in 2014 and new 
HIV infections among children had declined by 58% since 2000. Though 220 000 [190 
000–260 000] children became newly infected with HIV in 2014, this represents a 
significant drop from the 520 000 [470 000–580 000] new infections among children in 
2000 (1). This is an indication that the world is doing better in preventing new HIV 
infections among children, but that more efforts are still needed in order to bridge the 
lingering gap in pediatric HIV treatment (1).  
In line with this concern, on August 6th 2014, the U.S. President’s Emergency Plan 
for AIDS Relief (PEPFAR), in partnership with the Children’s Investment Fund Foundation 
(CIFF), launched the “Accelerating Children’s HIV/AIDS Treatment (ACT)” initiative. ACT 
is an ambitious $200 million initiative to double the number of children receiving life-saving 
antiretroviral therapy (ART) across ten priority African countries including Cameroon over 
the next two years (8). During the launching of the ACT, Ambassador Deborah L. Birx, 
U.S. Global AIDS Coordinator said “Together, we must act swiftly, and with a focus on 
impact and geographic efficiency, to hasten the day when no child dies of AIDS. PEPFAR 
is committed to helping achieve an AIDS-free generation, and ACT is a bold step in that 
direction” and Jamie Cooper-Hohn, co-founder of CIFF, a London-based philanthropic 
foundation said "We must close the alarming treatment disparity between adults and 
children, it is immoral not to act especially when we now know that with treatment children 
with HIV can aspire to full and healthy lives”(9).These declarations and commitment 
clearly show that as from August 2014, pediatric HIV care and treatment priority was 
highest in the international agenda.  
I.2. Rational of the study    
The Cameroon Ministry of Public Health with support from global initiatives including 
UNITAID, Clinton Health Access Initiative, the Global Fund to fight AIDS, Tuberculosis 
and Malaria and the President’s Emergency Fund for AIDS Relief (PEPFAR) is providing 
HIV testing and antiretroviral drugs free of charge for children under the age of 15 years. 
Yet, as it is the case at the global level, children are still lagging behind in accessing 
pediatric HIV care and treatment in this country. Though multiple factors may account for 
the current low uptake of pediatric ART in Cameroon, the lack of the implementation of 
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an adequate strategy for early identification of HIV infected children and linkage to care 
is the main barrier for the HIV treatment gap for children in this country.  
Actually, if there are some visible efforts in promoting the early infant diagnosis (EID)-
PCR testing as the standard strategy for identification of children below the age of 18 
months, the implementation of a clear strategy to identify HIV infected children older than 
18 months (older children) and link them into care is lacking in the field. The subpopulation 
of HIV infected children below the age of 18 months in Cameroon represents only 15% 
of the total population of children living with HIV/AIDS in the country (10). This implies 
that focusing mainly on EID-PCR strategy, 85% of children living with HIV/AIDS may not 
be identified early for timely enrolment in HIV care and treatment. Hence, in addition to 
the EID-PCR strategy, there is need for a robust strategy to identify older children as well 
as adolescents living with HIV/AIDS and link them to HIV care and treatment services. In 
this regards, the World Health Organization (WHO) recommended in 2007, the provider-
initiated-testing and counseling (PITC) as the standard strategy for identification of HIV 
infected children and adolescents and with enrollment of  positive cases in care (11). The 
PITC guidelines state that health care providers should systematically propose HIV 
testing to all children seen in a health facility irrespective of the presenting complaints 
(11). For the purpose of this study, we will name this PITC approach “blanket PITC 
(bPITC)” in the sense that all children seen in the hospital are supposed to be tested for 
HIV. The current low pediatric ART coverage suggests that bPITC is not achieving the 
desired results and this gap prompts the need to strengthen the implementation of this 
strategy    but most importantly to investigate more effective HIV testing approaches for 
children in Cameroon. 
To further guide case identification of pediatric HIV/AIDS, WHO and UNICEF jointly 
released in 2010 a policy brief recommending to heath care providers to emphasize HIV 
testing and counseling for all infants born to HIV-positive women as well as for children 
from families where another sibling or parent has already been diagnosed with HIV (12) 
as a routine component of follow-up care for HIV-exposed children, . For the purpose of 
this study, we will call this PITC approach “targeted PITC (tPITC)” in the sense that this 
approach requires care providers to systematically offer HIV testing to children of parents 
living with HIV/AIDS. So far, there is a dearth of literature in the implementation of tPITC 
among children and adolescents, suggesting an implementation gap of this PITC 
approach globally and in Cameroon in particular. Most importantly, there is lack of 
18 
 
knowledge on the comparative advantages of tPITC over bPITC in terms of acceptability, 
feasibility and effectiveness .  
 I.3. Goal of the study 
This study aimed at bridging the knowledge gap on implementation outcomes of 
both targeted and blanket PITC in order to provide evidence needed by policy-makers 
for programming more effective pediatric and adolescents HIV treatment services in 
Cameroon.    
I.4. Objectives of the study 
I.4.1. Primary objective 
To assess the effectiveness of targeted PITC (tPITC) in comparison to blanket 
PITC (bPITC) in the identification and linkage to antiretroviral therapy (ART) of infants, 
children and adolescents in Cameroon. 
1.4.2. Secondary objectives 
i) To assess the acceptability of tPITC in comparison to bPITC among parents 
accessing health care services in 3 health facilities in Cameroon; 
ii) To assess the feasibility of tPITC in comparison to bPITC in 3 health facilities in 
Cameroon;  
iii) To assess barriers and enablers to HIV testing and treatment for children and 
adolescents in 3 health facilities in Cameroon 
iv) To assess the combined effect of the implementation of both tPITC and bPITC in the 
uptake of pediatric HIV services (HIV testing, newly diagnosed HIV cases and ART 
enrolment) in 3 health facilities in Cameroon    
I.5. Significance of the Study 
This study will inform on the effectiveness of both tPITC and bPITC strategies in 
case identification and linkage of HIV infected children and adolescents in HIV treatment 
services in Cameroon. Most importantly, it will determine the incremental number of HIV 
positive children and adolescents the tPITC can identify and link to treatment in 
comparison to the commonly used bPITC approach.  
19 
 
The knowledge generated by this study will complement the existing evidence on 
the effectiveness of PITC and further guide how best this strategy should be implemented 
in a most effective manner in order to achieve an AIDS –free generation in a shortest 
possible time in Cameroon.   
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II.1. Service delivery of pediatric HIV care and treatment 
The provision of effective pediatric HIV care and treatment requires that HIV 
infected children are i) identified early enough, ii) linked to care, iii) initiated on ART, iv) 
retained in care and v) monitored to achieve viral suppression necessary to control HIV 
infection. The completion of this cascade is required for a pediatric HIV treatment program 
to be effective. However, in resource limited settings, HIV testing in infants, children and 
adolescents is performed most often when these children are already presenting with 
clinical manifestations of HIV/AIDS.     
The antenatal clinics (ANC) is an important entry point for HIV testing for pregnant 
woman but also for identification of pediatric HIV cases through HIV positive mothers 
diagnosed during ANC. However, despite an ANC attendance coverage of  82.8% in 
Cameroon, the HIV testing uptake among pregnant woman is 56,4% (13).  This is due to 
numerous challenges affecting the prevention of mother to child transmission of HIV 
(PMTCT) program including large proportions of home deliveries, fear of the cultural 
implications of a positive HIV test result, such as the lack of male partner support and 
even violence [(14), (15), (16)]. Consequently, children are started on ART at an 
advanced stage of the disease, where ART outcome is already compromised. 
 Marston et al.  found that among older African children with perinatally acquired 
HIV infection; most already suffer severe symptoms at the time of diagnosis, including 
profound growth retardation (17). Conversely, most HIV infected children in resource-rich 
countries are diagnosed and treated early with ART [(18), (14), (15)].   This has 
dramatically modified the course of HIV infection in children in these countries, reducing 
mortality by fivefold or more and resulting in high survival rates (> 90%) into adulthood 
((20),(21)). For example, in the United Kingdom, the average age of children infected peri-
natality with HIV is estimated at 13.2 years (22) while in New York City (United States) 
76% of these children are between the ages of 13 and 24 years (23).  Newell at al. 
reported that in the absence of HIV testing and timely ART initiation, one third of infants 
living with HIV die before their first birthday, half die before the age of 2 years and about 
75% will not reach their fifth birth day (24). The current low pediatric ART coverage in 
Cameroon suggests that many infants, children and adolescents are dying in the 
community without appropriate care.  
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II.2. Overview of HIV testing and counseling strategies 
among children and adolescents  
The WHO recommended provider-initiated-testing and counseling (PITC) is the 
standard strategy for identification and linkage of HIV positive children into care and 
treatment. The implementation modalities of PITC include: the blanket PITC (bPITC) 
approach where all children seen in a health facility are offered an HIV test irrespective 
of the presenting complaint (11) and the targeted PITC (tPITC) where HIV testing and 
counseling is systematically offered to children from families where a parent or another 
sibling has already been diagnosed with HIV. Moreover, the US President’s Emergency 
Fund for AIDS Relief (PEPFAR) recommends an aggressive HIV testing targets among 
HIV affected children using the family centered approach for HIV testing and counseling 
(25). The current gap in pediatric ART coverage globally and in Cameroon in particular 
prompts the need to investigate the barriers impeding the effective implementation of 
these strategies.   
II.3. Implementation outcomes of provider-initiated-testing and 
counseling among children   
In Cameroon, literature on PITC (both targeted and blanket) implementation 
outcomes among children is scanty. Nevertheless, the Batibo District Hospital located in 
rural North West Region of Cameroon, piloted the tPITC in 2006 through the “Active 
Search for Pediatric HIV/AIDS” (ASPA) project that was designed to promote HIV testing 
among children born to HIV infected parents diagnosed with HIV or receiving HIV services 
in the hospital. The ASPA project screened 198 children, 36 (18,2%) were found HIV 
positive and 24 (67.9%) were linked to care, resulting to a substantial  increase in pediatric 
ART coverage in that hospital (26). This is an indication that tPITC is feasible even in 
rural health care settings and can contribute in bridging the current gap in pediatric ART 
coverage in Cameroon. 
 Furthermore, the association of PITC (blanket) with increased enrollment of 
children in care and treatment has been demonstrated in many Sub-Saharan countries 
(21). Torbunde et al. reported among 18 months to 18 years old children accessing health 
care in 18 health facilities in Nigeria, an overall 37.8% increase in new enrollments in 
care, and 86% increase in new enrollments on ART in the 12 months after, compared to 
the 12 months preceding PITC training and implementation. This study found a high client 
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acceptance proportion   for PITC at 99.4% and 8.4% of tests were positive. The most 
common reported reasons for PITC non or poor implementation in this study were the 
lack of rapid test kits, the poor commitment from facility leadership and the lack of funds 
(22). Kranzer et al. in a study assessing  PITC implementation among children aged 6-15 
years old in 6 primary health care clinics in Harare, Zimbabwe found that among 2831 
eligible children, 2151 (76%) were offered PITC, of whom 1534 (54.2%) consented to HIV 
testing, 82 (5.3%) children tested HIV-positive, with 95% linking to care (29). Most 
importantly, this study revealed that more than 90% of children who tested HIV-positive 
had had previous contact with health services, indicating the potential impact of consistent 
implementation of PITC in reducing missed opportunities to identify and linked children 
into care. Moreover, parents/guardians consent was reported as the key barrier to PITC 
as 29% of children eligible were not tested because parents did not provide consent for 
testing their kids. Other barriers to PITC (blanket) identified by this study included the lack 
of staff training in PITC as well as the lack of HIV testing kits.  
The above evidence indicates that PITC is effective in increasing enrollment of HIV 
infected children into care. However, the implementation of this strategy is challenged by 
factors such as lack of staff training, stock out of HIV testing kits, poor commitment from 
facility leadership and lack of parental consent for HIV testing of children. According to 
Davies MA and Kalk E, barriers to implementation of this strategy are multifactorial, 
operating at the level of the individual, health care facility, community, and national legal 
framework (30). These barriers may also be contextual, indicating the need to investigate 
the pattern in Cameroon to inform policy.    
II.4. Effectiveness of Provider-initiated-testing and counselling  
The evidence on the effectiveness of PITC in identifying and linking children in 
HIV care is compelling as demonstrated in section 2.3 above. However, there is need to 
identify the best approach to deliver PITC in a cost-effective manner. To the best of our 
knowledge, a part from the ASPA project reported by Yumo et al. (26) , the PITC 
implementation approach published in the literature is the “blanket PITC” whereby 
children are tested for HIV at a given medical encounter irrespective of the presenting 
complaints [(27),(28),(29)]. This blanket PITC (bPITC) approach requires a lot of 
resources in terms of testing kits and supplies in addition to the increased work load on 
the already overburdened health personnel. In contrast, the targeted PITC (tPITC) 
approach used in the ASPA project whereby children born to HIV infected parents and 
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those with clinical signs and symptoms of HIV infection are targeted for testing seems 
cost-effective. In Cameroon, the ASPA project found 36 HIV infected children out of 198 
tested in one rural health facility (26).  This result is in sharp contrast with the outcome 
of the bPITC approach reported by Kranzer et al. from Zimbabwe where in 6 health 
facilities, 1534 children were tested for 82 (5.3%) children tested HIV-positive (29).   
Considering that the HIV prevalence in the adult population in Zimbabwe is almost three 
times higher than   that of Cameroon (19% vs 4,3%) but that ARV prophylaxis coverage 
to prevent mother to children transmission (PMTCT) is almost twice in Zimbabwe as 
compared to Cameroon (56% vs 32,7%) (1), it is not possible to conclude on the 
effectiveness of one testing approach over the other. Though the ASPA approach 
seems more effective, additional data comparing these 2 models are needed to draw a 
valid conclusion and better inform pediatric HIV services design and implementation. 
Moreover, the implementation of both tPITC and bPITC in a hospital should have a 
meaningful impact in the uptake of pediatric HIV services in this health facility. There is 
a knowledge gap on the outcome of the combined effect of both tPITC and tPITC in the 
uptake of HIV services among children and adolescents. 
II.5.  Linkage to care of HIV infected children and adolescents 
The functions of PITC include diagnosis, linkages and access to HIV-related 
services (12).   Hence, linkage to care is an important step before retention. If  data on 
retention and factors associated with attrition in pediatric HIV programs in Sub-Saharan 
African countries have been published [(31), (32), (33),(34), (35), (36)] information on  
linkage to care after HIV testing are scarce, even for adults HIV program (37). Most 
importantly there is a scientific gap on the outcome of linkage in tPITC and bPITC.  To 
optimize HIV care in children in Cameroon, there is need to assess the outcome of linkage 
to care in different PITC implementation approaches (tPITC and bPITC).     
 
II.6. Outcome of provider-initiated testing and counseling 
  PITC is an effective strategy in increasing enrollment of children in HIV care and 
treatment if the aforementioned implementation barriers are addressed accordingly. 
However, it is still not clear how best PITC should be delivered in a cost-effective and a 
more sustainable way. The sustainability of the blanket PITC approach might be 
compromised by the associated high cost. 
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 On the contrary, we believe that the targeted PITC (tPITC) is more effective as 
compared to the blanket PITC (bPITC) which is widely published [(27),(29)]. Actually, 
more than 90% (38) of pediatric  and 72% (39) of adolescents HIV infections are from 
vertical transmission, therefore we hypothesize that identifying HIV infected children 
through known HIV infected parents or siblings is a plausible high yield strategy. 
 Moreover, to ensure that children who are identified and linked to care remain in 
care, there is need to evaluate factors associated with retention into care in the context 
of Cameroon. Furthermore, it is of paramount interest to assess the barriers to 
implementation of both targeted and blanket PITC in the context of Cameroon. This 
information is needed to optimize HIV testing uptake, care and treatment among children 
and adolescents in this country.     
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CHAPTER III: MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
III.1. Study type 
We conducted a cross sectional study assessing and comparing the outcomes of 
tPITC versus bPITC in identifying and linking HIV infected children in care and 
treatment. Also, we assessed barriers and enablers to HIV testing and treatment for 
children and adolescents by evaluating the knowledge, attitudes and practices of people 
living with HIV/AIDS and health personnel regarding HIV testing and treatment for 
children. In addition, the study assessed the combined effectiveness of tPITC and 
bPITC through a retro-prospective analysis of routine data.  
III.2. Study setting 
The study was conducted in 3 health facilities in Cameroon namely: the Limbe 
Regional Hospital (LRH) in the South West Region of Cameroon, the Ndop District 
Hospital in the North-West Region of Cameroon and the Abong-Mbang District Hospital 
in the East Region of Cameroon.  
III.2.1. Limbe Regional Hospital   
The LRH is the main 2nd referral level public health facility serving  a population of 1 
384 286 disseminated in the South West Region of Cameroon (3). It has a capacity of 
200 beds and provides comprehensive and continued health care services including the 
management of tuberculosis and HIV/AIDS. In 2013, this hospital had a monthly average 
of 1248 new patients (outpatient consultations) including 224 children (<15 years) and 
1024 adults (≥15 years). This same year, there were also in this hospital 3021 patients 
on antiretroviral therapy (ART) amongst whom 76 where children below the age of 15 
years.  
III.2.2. Ndop District Hospital   
  The Ndop District Hospital (NDH) is the 1st referral government health facility 
serving a    population of 195 000 inhabitants. This hospital is located in a rural area in 
the North West Region of Cameroon and has 3 medical doctors, 22 nurses and 7 
laboratory technicians. It has a capacity of 87 beds and provides comprehensive and 
continued health care services including the management of tuberculosis and HIV/AIDS. 
In 2013, this hospital had a monthly average of 1500 new patients (outpatient 
consultations) including 270 children (<15 years) and 1230 adults (≥15 years). This same 
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year, there were 2 464 patients on antiretroviral therapy (ART) amongst whom 118 where 
children below the age of 15 years enrolled in HIV care in this hospital. 
III.2.3. Abong Mbang District Hospital   
The Abong-Mbang District Hospital is the 1st referral government health facility serving 
a   population of 69 712 inhabitants. This hospital is located in a rural area in the East 
Region of Cameroon and has 3 medical doctors, 35 nurses and 3 laboratory technicians. 
It has a capacity of 60 beds and provides comprehensive and continued health care 
services including the management of tuberculosis and HIV/AIDS. In 2014, this hospital 
had a monthly average of 380 new patients (outpatient consultations) including 78 
children (<15 years) and 302 adults (≥15 years). This same year, there were 1133 
patients on antiretroviral therapy (ART) amongst whom 50 where children below the age 
of 15 years enrolled in HIV care in this hospital.  
III.3. Study period 
  The ASPA study was conducted from July 2015 to November 2016. Data were 
collected during a 6-month enrollment period from July 2015-December 2015 in the Limbe 
Regional Hospital and from June 2016-November 2016 in Abong-Mbang and Ndop 
District Hospitals. This enrolment period corresponds to the time where parents and 
children were invited to participate in the study.   
III.4. Study population 
The study participants were: i) parents/guardians accessing HIV services or 
accompanying their children for consultations at the outpatient department of respective 
hospitals; ii) children of HIV infected parents accessing HIV care in the hospital, iii) 
children consulting at the outpatient department for any reason; iv)   health personnel 
involved in children’s consultations.   
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III.5. Selection Criteria 
III.5.1. Inclusion criteria 
i). HIV infected parents: Parents diagnosed with HIV infection or receiving HIV services 
in the hospital and consenting to participate will be eligible for enrollment in the study.  
ii). Parents/guardians seeking care for their children in the hospital:  
Parents/guardians presenting at the hospital with sick children will be enrolled in the study 
irrespective of the motive of consultations for their children. 
iii). Children of HIV infected parents: Children of HIV infected parents aged between 6 
weeks to 19 years old will be eligible for enrollment in the study. Parents/guardians 
consent will be required as well as assent of older children. 
iv). Children consulting in the hospital: Children aged 6 weeks to 19 years old 
consulting in the hospital for any reason will be eligible to participate in the study. 
Parents/guardians consent will be required as well as assent of older children. 
vi). Health personnel: Health care providers involved in HIV testing and treatment for 
children and consenting to participate were enrolled in the study.  
III.5.2. Exclusion criteria  
i)HIV status: children with known HIV positive status were excluded from the study. 
ii) Age: children below the age of 6 weeks or above 19 years were excluded in the study. 
iii) Health conditions: children or parents who were critically ill were excluded from the 
study. 
III.6. Study context, site preparation and implementation strategies  
The study was conducted within the Active Search for Pediatric HIV/AIDS (ASPA) 
project, an initiative of R4D International Foundation, a Cameroon-based global health 
research non-governmental organization. The ASPA project aimed at promoting pediatric 
HIV services delivery in Cameroon and this through a range of activities including: 
capacity building of health personnel, services delivery both at facility and community 
level, nutritional support, monitoring and evaluation.  
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 Prior to the implementation of the study, the inputs and supports provided by the 
project to respective hospitals included the following: staff training on both bPITC and 
tPITC implementation, provision of HIV testing kits and sites monitoring. In addition, the 
study provided to each hospital 3 dedicated staff (2 data collectors and 1 data manager) 
to support the implementation of the project as follows: one staff was posted at the HIV 
treatment center to ensure that all parents receiving HIV care are counselled and enrolled 
in the study, and that their children are tested and positive cases linked to care 
accordingly. The 2nd staff was posted at the outpatient department (OPD) of the hospital 
to ensure that all children consulting are counselled, enrolled, tested and positive cases 
are linked to care as well. The 3rd staff was responsible for the overall coordination of site 
activities, ensuring compliance of the study protocol and quality in the data collection and 
management process in both groups. In addition, in both groups, community health 
workers (hospital staff) were involved in counselling, follow up, reminder calls and home-
based testing when applicable.  
It should be noted that in Abong-Mbang and Ndop District Hospitals, the ASPA 
project provided transport reimbursement to parents in the tPITC group to bring their 
children to the hospital for HIV testing, and nutritional kits (sugar, oil, milk and rice) to HIV 
positive children in care. These supports were not available in Limbe Regional Hospital 
during the study period.    
III.7. Sampling, recruitment of participants and study procedures  
i) Sampling: Parents and children eligible for the study were enrolled consecutively till 
completion of the 6 months enrolment period in respective site.  
 ii) Recruitment of participants:  Participants (parents and children) in the study were 
recruited for a period of 6 months in respective group as follows: 
➢ Blanket PITC (bPITC): All parents/guardians accompanying sick children and 
adolescents aged  6 weeks to 19 years for consultations at the Outpatient 
Department of Hospital (OPD) were counselled and invited by a trained counsellor 
to have their children tested for HIV irrespective of the presenting complaint. After 
the consent of parents, assent to participate was requested for children above 11 
years prior to enrolment in the study. Consenting parents and assenting children 
when applicable were all enrolled in the study.      
31 
 
➢ Targeted PITC (tPITC ): All parents living with HIV/AIDS accessing HIV services 
in the hospital were counselled and invited by a trained counsellor to have their 
children aged 6 weeks to 19 years of unknown HIV status tested for HIV.  These 
parents were approached for enrolment during their contact with the HIV treatment 
center for ARVs drugs initiation or monthly refill. After the consent of parents, 
assent to participate was requested from children above 11 years prior to 
enrolment in the study. Consenting parents and assenting children when 
applicable were all enrolled in the study. In this group, parents were given the 
opportunity to bring their children in the hospital for testing and to have their 
children tested at home by community home workers. For parents who opted to 
have their children tested in the hospital, they were asked to bring children to the 
hospital for testing during their next visit at the HIV treatment center, most often 
the next month following enrolment. For parents who opted to have children tested 
at home, they made an appointment with a community health worker on the day 
and time for the home visit (Figure 3.1).   
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Figure 3.1:  ASPA study flow 
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iii) HIV testing and counselling procedures 
The HIV testing was conducted following the Cameroon’s national algorithm for 
HIV testing and counseling in children described below. In particular, pre and post 
counseling were done to parents/children before and after the test. In the targeted PITC 
arm, children were tested for HIV either in the health facility or at home and this at the 
convenience of the parents. The community HIV testing was done by trained community 
health workers.   
➢ 6 weeks ≤ children < 18 months old:  In this subgroup, trained laboratory 
technicians or community health workers   used dried blot spot (DBS) to collect 
blood specimen that was   shipped to the national reference laboratory (NRL) for 
HIV testing using polymerase chain reaction-deoxyribonucleic acid (DNA-PCR) 
molecular techniques. The shipment of specimens was done using the national 
routine DBS-PCR transportation system of the Ministry of Public Health. Actually, 
the DBS were shipped to the nearest NRL to the collection sites as follows: i) the 
Cameroon Baptist Convention   Mutenguene Laboratory for specimen from the 
the Limbe Regional Hospital, ii) The Fondation Chantal Biya Laboratory for 
specimen from the Abong District Hospital and iii) the Bamenda Regional 
Hospital Laboratory for specimen from the Ndop District Hospital. The HIV testing 
was done using the PCR procedures of respective laboratory and the results 
were send to respective hospitals through the routine mail channel.  
➢ 18 months ≤ children ≤ 19 years old: In this subgroup, HIV testing was  done 
using 2 rapid tests: the rapid test 1 (RT1) was  more sensitive while the rapid test 
2 (RT2) was  more specific. We used  Alere Determine HIV-1/2  ( Paul Hartman, 
AG Germany) for RT1 and Oraquick (Alere Medical Co Ltd, Japan) for RT2. The 
HIV testing was  done by trained laboratory technicians or community health 
workers. The child was  declared HIV negative if he/she was tested negative on 
RT1. The child was declared HIV positive if he/she was tested positive for both 
RT1 and RT2 (Figure 3.2). For community HIV testing, only RT1 was used for 
screening (finger prick). Children found positive on RT1 at community level was 
invited to come to the hospital where RT2 was done for confirmatory. If a child was 
positive on RT1 and negative on RT2, he/she was declared indeterminate. In such 
cases, the child was test with PCR-DNA when feasible. If not, the test (RT1+RT2) 
was repeated after 3 months. The results of the test was  declared to the parents 
34 
 
and also to the children  by trained counselors. In particular, HIV positive results 
were declared to children  with  the parents’ consent, and this depending on the 
age (above 11 years) of the child as well as the psychological readiness as 
determined by the counselors. 
 
iv) Linkage to care 
Children and adolescents tested HIV positive were assessed according to national 
guidelines for ART eligibility. This assessment will include WHO clinical staging and 
baseline biological analysis including the following blood tests: CD4 count, full blood count 
and transaminases (ALAT/ASAT).  
ART initiation and clinical monitoring of HIV positive children was done according to the 
Cameroon national guidelines. These guidelines were in line with WHO 2013 guidelines:  
HIV infected children less than 5 years irrespective of CD4 count level and children above 
5 years with CD4 count < 500 cells/mm3 were initiated on ART (40). The national 
guidelines were later revised to align with the WHO 2015 guidelines. With these new 
guidelines, all HIV infected children were initiated on ART irrespective of the CD4 count 
level and the age (41). Regarding clinical monitoring after initiation, children were 
reassessed clinically after 3 months; thereafter clinical and biologically (Full blood count, 
CD4 count,…) monitoring were done every 6 months.    
The HIV testing and ART enrolment procedures are summarized in the figure 3.2 below. 
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                              Figure 3.2: HIV testing algorithm, ASPA Study  
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III.8. Data collection and management 
III.8.1. Data collection tools 
  Data were collected using structured and standardized pre-tested questionnaires 
described as follows:  
Questionnaire No 1: This questionnaire was used to collected information of 
parents living with HIV/AIDS and receiving HIV services in the hospital. Among others, 
the following socio-demographic information were collected: name, contact details, age, 
sex, residence, profession, education level, marital status, ARVs drugs status,  number 
of children less than 19 years, number of  children less than 19 years with unknown HIV 
status, willingness to test children with unknown HIV status, preferred site to test children 
of unknown HIV status (Annex 4). Information generated by this questionnaire were used   
to assess the HIV testing acceptance proportion  among parents regarding tPITC. This 
HIV testing acceptance proportion  was  used as the measurement of  acceptability of 
targeted PITC among parents in the study site.  
Questionnaire No 2: This questionnaire was used to collected information of 
parents/guardians accompanying their children to the hospital. Among others, the 
following socio-demographic information were collected: name, contact details, age, sex, 
residence, profession, education level, marital status, HIV status, number of children 
brought to the hospital, willingness to test child (ren) for HIV (Annex 5). Information 
generated by this questionnaire were used   to assess the HIV testing acceptance  among 
parents regarding bPITC.   This HIV testing acceptance   was  used as the measurement  
of  acceptability of the  blanket PITC among parents in the study site.  
Questionnaire No 3: Children Enrolment form tPITC.  This questionnaire was used 
to collect information of children born to parents living with HIV/AIDS. Among others, the 
following information were collected: Age, sex, education level,  identified for HIV testing 
through, HIV testing status, HIV status, mother and father occupation, mother and father 
living status, site for HIV testing, HIV testing result, ART clinical and biological 
assessment results (WHO  clinical stage, CD4 count) for HIV positive children (Annex 6).   
 Information generated by this questionnaire was used to assess   the number of 
children   tested for HIV (feasibility), the number of children newly diagnosed with HIV 
(case detection or yield), the number diagnosed with HIV per WHO staging (case 
detection earliness) and linkage to care  ) in the targeted PITC. These 4 indicators were   
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used to determine the HIV testing uptake (feasibility), yield (or case detection), case 
detection earliness and linkage to care in the targeted PITC strategy.   
Questionnaire No 4: Children enrolment form bPITC.  This questionnaire was used 
to collect information of sick children consulting at the outpatient department (OPD). 
Among others, the following information were collected: age, sex, education level, brought 
to the hospital by,  HIV testing status, HIV status, mother and father occupation, mother 
and father living status, HIV testing result, ART clinical and biological assessment results 
(WHO  clinical stage, CD4 count) for HIV positive children (Annex 7).   
Routine data forms: This form was used to collect in respective health facility the 
following information: number of consultations of children and adolescents (6 weeks to 
19 years) at the outpatient department, number of children tested for HIV, number of HIV 
cases identified among children, number of HIV positive children enrolled on ART (Annex 
8). This information was extracted from consultations, laboratory, and ART registers and 
this retrospectively and prospectively at least 6 months before and after the 
implementation of the study in respective hospital. This data was used to assess the effect 
of the implementation of PITC (both targeted and blanket approaches) in HIV testing 
uptake, newly diagnosed cases and ART enrolment among children and adolescents in 
the study site.  The information was also used to assess the combined effect of the 
implementation of both tPITC and bPITC in respective hospitals.  
Parents living with HIV/AIDS survey form: In each site, we interviewed 
participants among a subgroup of people living with HIV/AIDS (PLHIV) who do not 
return with their children to the hospital for testing and this in order to find the reasons of 
not respecting the appointment (reasons for non-return).  The information collected in 
this form were: travel distance to the hospital, reasons for not returning to the hospital 
with the child for HIV testing, willingness to have community health workers test the 
child at home, HIV disclosure to the partner/spouse (Annex 9).  
Health personnel survey form:  In each site, we also interviewed health care 
providers involved in clinical care for children and this to assess their knowledge, 
attitudes and practices regarding HIV testing, counseling and treatment for children and 
adolescents in their respective health facilities. The information collected in this form 
were: last time to consult a child, HIV testing requested to the last child consulted, 
reasons for not requesting HIV testing to children all the time, last training on pediatric 
HIV testing and counselling (Annex 10).  
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III.8.2. Data management   
  Following data collection, completed questionnaires were stored in a secured 
cupboard with lockers. The questionnaires were later di-identified by removing all 
information (name and contact details) that can link the participants with the data. Only 
the study code was left on the questionnaires that were entered in a database   developed 
for data entry using Access 2016 (Microsoft®).  Data entry were done progressively in a 
database by a trained data clerks and this using a laptop. To enhance data quality and 
accuracy, the copy of the database was transferred to the data manager together with 
the questionnaires. The data manager   conducted a double entry verification on a sample 
(30%) of questionnaires and this to correct any discrepancies observed and clean 
inaccurate data.  Once data entering was validated, questionnaires were   safeguarded 
in a cupboard. The database was also safeguarded in an external hard drive.   
III.8.3. Data analysis 
The results were reported using both descriptive and analytical statistics. The 
study population characteristics were determined by generating frequency distributions in 
2x2 tables per study site and groups (tPITC or bPITC). Univariate analysis was used to 
compare variables between groups. Chi-square test (X2) was used to determine the 
association of population characteristics or outcome measures per study group.  The 
confidence interval and/or statistical significance were calculated at 5% level.  Data 
analysis were done using STATA 2013 (College Station, TX: StataCorp LP).      
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III.9. Definitions of terms and outcome measures  
The outcome measures were defined and calculated as described in the table below 
(Table 3.1).  
 
Table 3.1:  Definition of terms and calculation of outcome measures   
Outcome Numerator Denominator Programmatic 
definition 
 
 
 
 
 
 
Effectiveness:  
This is a 
composite 
outcome 
measured by 3 
sub-outcomes: 
i) case 
detection, ii) 
case detection 
earliness and 
iii) linkage to 
care 
Case detection 
(yield/prevalence) 
Number of 
children 
tested HIV 
positive 
Number of 
children 
enrolled in 
the study and 
having a 
conclusive 
HIV test 
result (HIV 
positive or 
negative) 
The case 
detection 
assesses the 
likelihood of the 
strategy (tPITC or 
bPITC) to detect a 
new case 
Case detection 
earliness  
Number of 
children 
tested HIV 
positive at 
WHO stage 
1 (per  
study 
group) 
Number of 
children 
tested HIV 
positive in 
each group 
(tPITC or 
bPITC) 
The case 
detection 
earliness 
assesses the 
likelihood of the 
strategy to detect 
cases earlier 
Linkage  Number of 
HIV 
positive 
children 
enrolled on 
ART 
Number of 
children 
diagnosed 
HIV positive 
The linkage 
assesses the 
likelihood of 
linking a case to 
care in each study 
group (tPITC or 
bPITC)   
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Acceptability:   
This outcome 
measures the 
readiness or 
willingness of 
parents to 
accept having 
their children 
tested for HIV. 
Studies on 
acceptability of 
HIV testing 
strategies have 
been widely 
published (38).          
Acceptance  Number of 
parents 
counselled 
for HIV 
testing of 
their 
children   
Number of 
parents who 
accepted to 
have their 
children 
tested for HIV 
The acceptability 
assesses the 
attitude of 
parents/caregivers 
to opt in for HIV 
testing for their 
children.  
Feasibility: 
This outcome 
assesses the 
practicability of 
the strategy or 
the potential to 
test eligible 
children. 
Studies on 
acceptability of 
HIV testing 
strategies have 
been widely 
published 
(39),(40),(41).  
 
 HIV testing 
uptake  
Number of 
children 
tested for 
HIV 
Number of  
eligible 
children 
identified in 
respective 
study group 
The feasibility 
outcome 
assesses the 
capacity of the 
health facility to 
routinely test all 
eligible children  
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Combined 
effectiveness 
of tPITC and 
bPITC: This is 
a composite 
outcome 
measuring the 
cumulative 
impact of both 
tPITC and 
bPITC in terms 
of HIV testing 
uptake, case 
detection and 
linkage and 
this  before 
and after the 
implementation 
of the study 
Cumulative HIV 
testing uptake   
Number of 
children 
tested in 
the hospital 
over a 
period of 
time 
Number of 
children who 
consulted at 
the hospital 
over the 
same period 
of time 
The cumulative 
HIV testing uptake 
assesses the 
impact of the 
implementation of 
both tPITC and 
bPITC in the 
same hospital. It 
informs on the 
relevance of 
implementation of 
both strategies at 
the same time in 
order to improve 
HIV testing 
uptake.  
Barriers to 
pediatric HIV 
testing, 
counselling 
and treatment   
 
The analysis of the survey amongst people living with HIV/AIDS and 
health personnel regarding their attitudes and practices towards 
PITC will determine the barriers or the enablers to PITC. This 
information will inform policy for better planning of pediatric HIV 
services   
 
III.10. Ethical considerations 
III.10.1. Informed consent and assent 
Participation in the study was voluntary. Informed consent (Annex 11) was 
obtained from the parents/guardians as well as health personnel prior to the enrolment 
of their children into the study. In addition to the parents’ consent, older children more 
42 
 
than 11 years (adolescents) had to provide assent (Annex 12) prior to enrolment into 
the study.  
  The ASPA study received ethical approval from the Cameroon National Ethics 
Committee, the Ludwig-Maximilians-Universität, Munich (Germany) and the Albert 
Einstein College of Medicine (NY, US). In addition, the study received an administrative 
authorization from the Cameroon Minister of Public Health.  
  
III.10.2. Potential risks 
i) Confidentiality: The study participants were exposed to breach of confidentially 
(e.g: HIV positive status). To minimize this risk, project staff were sensitized on 
confidentially norms and   signed a confidentially agreement form prior to the start of the 
study. In addition, a logbook was used to create study code for each participant. The 
study code was used for data entry and analysis. Hence, personal identifiers such as 
names, addresses, phone numbers or other information that can lead to participants’ 
identification during or after the study were not entered into the database. However, 
regarding the quantitative part of the study, dedicated health care providers alone and 
this for follow up purpose, will be able to query the logbook study code and linked the 
study code and patient’s medical files.     
ii) Venipuncture: Children were exposed to the risk of venipuncture notably pains, 
excessive bleeding, hematoma (blood accumulating under the skin), infection and 
multiple punctures to locate the veins. These risks were minimal and similar to those 
encountered in standard practices. However, to minimize them, venipuncture was 
performed only by trained staff. In addition, we planned to provide free treatment   to 
children in case of injuries due to venipuncture. Fortunately, we did not have such a case.    
III.10.3. Risks in relation to benefits 
 Participants benefited early access to HIV diagnosis, early enrolment in care 
and/or treatment for children with HIV-infection, information on HIV infection and 
adherence. In addition, the knowledge generated by this study will be used to strengthen 
the pediatric HIV program with the aim to reduce HIV/AIDS related morbidity and mortality 
in the community. Hence, the study benefits outweigh the risks.  
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III.11. Study coordination team 
The ASPA study was implemented under the leadership and coordination of Dr 
Yumo Habakkuk (Principal Investigator) who was supervised by Dr Marcus Beissner and 
Prof Thomas Loescher from Ludwig Maximillian University of Munich, Germany and Prof 
Christopher Kuaban of the University of Bamenda, Cameroon. The coordination team of 
the project was based at Research for Development International Foundation (R4D 
International Foundation), Yaoundé (Cameroon) and the implementation was supported 
by field staff as described in the chart below (Figure 3.3).   
                         
 
 
Figure 3.3: ASPA study coordination team  
44 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER IV: RESULTS 
 
 
 
 
 
 
 
 
45 
 
IV. 1. Study cascade   
In both groups (tPITC and bPITC), 3699 parents were counselled for enrolment of 
whom 3666 accepted to participated in the study. 33 (0.89%) parents refused to 
participate. The majority of parents enrolled came from the bPITC group represented with 
2430 (66.3%) participants against 1236 (33.7%) from the tPITC group. Through these 
parents, 4 719 eligible children were identified and enrolled for HIV testing. Of those, 3 
594 were tested, 80 tested HIV positive and 55 enrolled on ART (Figure 4.4).  
                             
 
Figure 4.4: ASPA study cascade outcome 
Parents offered
enrollment = 3699
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enrolled=3666
tPITC-Parents
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tPITC-Children
enrolled=1990
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tPITC-Children
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tPITC-HIV+ children 
enrolled on ART=34
bPITC-Parents
enrolled=2430
bPITC-Children 
enrolled= 2729
bPITC-Children 
tested for HIV= 2465
bPITC-Children
tested HIV+=40
bPITC- HIV+ children 
enrolled on ART=21
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IV.2. Socio-demographic characteristics of parents/guardians 
Females were more represented in both groups as compared to males, but   
slightly higher in the bPITC group (80.3% vs 81.8%, p= 0.0254 ). Parents were older in 
the tPITC group (median age (years): 36 vs 31) and the age range 25-40 was 
predominant in both groups, but significantly higher in the tPITC group (75.0% vs 58.0%, 
p<0.00001). The majority of participants were farmers in the tPITC group (50.7% vs 
16.0%, p<0.00001). Parents having secondary/high school level were predominantly 
represented in both groups, but significantly higher in the  bPITC group (37.0% vs 49.2%, 
p<0.00001). Married participants predominantly higher in bPITC group (40.2% vs 64.9%, 
p=0.00001) (Table 4.2).   
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            Table 4.2: Socio-demographic characteristics of parents in tPITC and bPITC groups 
 
Characteristics 
tPITC bPITC   
Limbe 
Abong-
Mbang 
Ndop Total Limbe 
Abong-
Mbang 
Ndop Total 
n (%) n(%) n (%) N (%) n(%) n(%) n(%) N (%) P* 
                  
Sex                   
Male 68(20.8) 65(18.9) 111(19.6) 
244 
(19.7) 
138(13.6) 146(25.4) 158(18.8) 442(18.2) 
0.25475 
Female 259(79.2) 279(81.1) 454(80.4) 992(80.3) 875(86.4) 429(74.6) 684(81.2) 1988(81.8) 
Age (years)                    
Mean±SD 36.5±7.7 35.5±8.9 37.7±8.7 36.8±8.6 32.8±9.9 33.8±11.2 34.0±11.1 33.5±10.6   
Median[Q1,Q3] 
36.0[31, 
42] 
35.0[29, 
41] 
36.0[31, 
43] 
36.0[30, 
42] 
31[26,37] 32[25, 41] 32[26,39] 31[26,39]   
<25 9 (2.7) 42(12.2) 22(3.9) 73(6.0) 165(16.3) 135(23.5) 151(18.0) 451(18.6) 
<0.00001 
25-40 
266 
(81.3) 
243(70.6) 418(74.0) 927(75.0) 650(64.2) 277(48.2) 481(57.1) 1408(58.0) 
40-60 52(16.0) 59(17.2) 125(22.1) 236(19.0) 171(16.9) 149(25.9) 171(20.3) 491(20.2) 
>60 0 (0.0) 0(0.0) 0(0.0) 0 (0.0) 27(2.7) 14(2.4) 39(4.6) 80(3.2) 
Education level                   
None 3 (0.9) 5(1.5) 37(6.5) 45 (3.6) 21(2.1) 12(2.1) 24(2.9) 57(2.4) 
<0.00001 
Primary 
162 
(49.5) 
125(36.3) 422(74.6) 709(57.4) 223(22.0) 154(26.8) 294(34.9) 671(27.6) 
Secondary/high 
school 
137 
(42.0) 
214(62.2 106(18.9) 457(37.0) 468(46.2) 356(61.9) 371(44.0) 1195(49.2) 
University 25 (7.6) 0(0.0) 0(0.0) 25(2.0) 301(29.7) 53(9.2) 153(18.2) 507(20.8) 
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In the bPITC group, 4.9% (120/2430) of parents declared to be HIV+.  In the tPITC group, the large majority (94.9%) of   
parents were on ART, 22.2% have been on treatment for more than 10 years and 60.8% have not disclosed their HIV positive status 
to any of  their children. Most (93.6%) of these parents preferred to have their children tested in the hospital rather than in their homes 
(5.6%).   (Table 4.3).   
 
 
 
 
Occupation                   
Farming 54(16.5) 150(43.6) 423(74.9) 
627 
(50.7) 
40(4.0) 
130 
(22.6) 
219(26.0) 
389(16.0) 
<0.00001 
Trading 127(38.9) 48(14.0) 57(10.1) 232(18.7) 220(21.7) 51(8.9) 122(14.5) 393(16.2)) 
Office work 27(8.2) 8(2.3) 31(5.5) 66(5.3) 118(11.6) 70(12.2) 258(30.6) 446(18.4) 
Student 8(2.5) 14(4.1) 7(1.2) 29(2.3) 102(10.1) 54(9.4) 107(12.7) 263(16.8) 
Others 111(33.9) 124(36.0) 47(8.3) 282(22.8) 533(52.6) 270(46.9) 136(16.2) 939(38.6) 
Marital status                   
Married  
167 
(51.0) 
60(17.4) 269(47.6) 496(40.2) 723(71.4) 209(36.3) 644(76.5) 1576(64.9) 
<0.00001 
Single 
116 
(35.5) 
81(23.5) 64(11.3) 261(21.2) 212(20.9) 115(20.0) 139(16.5) 466(19.1) 
Cohabitating  7 (2.1) 156(45.3) 1(0.2) 164(13.2) 56(5.5) 220(38.3) 3(0.4) 279(11.5) 
Divorced/separated 3 (0.9) 4(1.3) 59(10.4) 66(5.3) 4(0.4) 13(2.3) 16(1.9) 33(1.4) 
Widow/Widower 34 (10.5) 43(12.5) 172(30.5) 249(20.1) 18(1.8) 18(3.1) 40(4.8) 76(3.1) 
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Table 4.3: HIV history of parents in the tPITC and bPITC groups 
Characteristics 
tPITC bPITC 
Limbe 
Abong-
Mbang 
Ndop Total Limbe 
Abong-
Mbang 
Ndop Total 
n (%) n(%) n (%) N (%) n(%) n(%) n(%) N (%) 
Sex                 
HIV status (only bPITC)                 
Positive 
  
52(5.1) 37(6.4) 31(3.7) 120(4.9) 
Negative 894(88.3) 370(64.4) 757(89.9) 2021(83.2) 
Unknown 67(6.6) 168(29.2) 54(6.4) 289(11.9) 
Currently on ART (only tPITC)                 
Yes 316(96.6) 305(88.6) 552(97.7) 
 
1173(94.9) 
  
No 11(3.4) 39(11.4) 13(2.3) 63(5.1) 
Duration on ARVs drugs  (only tPITC) only 
tPITC)         
0-5 years 36(14.1) 221(79.5) 316(66.0) 573(56.6) 
6-10 years 22(8.6) 52(18.7) 141(29.5) 215(21.2) 
>10 years 198(77.3) 5(1.8) 22(4.5) 225(22.2) 
Had disclose HIV to children (only tPITC)         
Yes, to all of them 29(8.9) 112(32.5) 227(40.2) 368(29.8) 
Yes, to some of them 23(7.0) 25(7.3) 68(12.0) 116(9.4) 
No,  to none of them 275(84.1) 207(60.2) 270(47.8) 752(60.8) 
Preferred site for HIV test of children (only 
tPITC)         
Hospital 315(96.3) 318 (92.5) 339(60.0) 972 (93.6) 
Home 12(3.7) 20 (5.8) 26(4.6) 58 (5.6) 
Indifferent 0 (0.0) 6(1.7) 2(0.4) 8 (0.8) 
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IV.3. Socio-demographic characteristics of children 
Children were almost twice as  younger in the bPITC group as in the  the tPITC (median age: 48 vs 96 months). The age range 
60-120 and 19-60 months were significantly more represented in the tPITC and bPITC group respectively (31.8% vs 27.0%, p<0.00001).   
In the tPITC group a large proportion (46.2%) of children had primary school level while in the bPITC group most (41.2%) children had 
no education. In both groups, the majority of children were identified for testing through their mother (75.1% vs 63.8%, p<0.00001). In 
both groups, almost all the mothers of the children attended ANC during their pregnancy (96.7% vs 94.9%, p<0.00001). The large 
proportion of children were delivered in a health facility in both the tPITC and bPITC group (90.5% vs 98.9%, p<0.00001), but only 29.4% 
of HIV infected mothers (tPITC group) received ARVs for   PMTCT during pregnancy (Table 4.4).   
Table 4.4: Socio-demographic characteristics of children in tPITC and bPITC groups 
Characteristics 
 tPITC bPITC   
Limbe Abong-
Mbang 
Ndop Total Limbe Abong-
Mbang 
Ndop Total 
n (%) n(%) n(%) N(%) n(%) n(%) n(%) N(%) P* 
                  
Sex 
Female 290(52.5) 199(49.8) 510(49.1) 999(50.2) 621(51.5) 313(50.2) 435(48.3) 1369(50.2) 
0.98045 
Male 262(47.5) 201(50.2) 528(50.9) 991(49.8) 584(48.5) 310(49.8) 466(51.7) 1360(49.8) 
Age (months) 
Mean ± SD 107.5± 61.2  85.95±62.5 100.32±58.0 99.4±60.4 75.4±69.4 66.0±60.3 82.8±69.1 75.7±67.4   
Median (Q1, Q3) 108(60,156) 72(36,132) 96(48,144) 96(48,144) 48(16,132) 48(18,96) 60(24,132) 48(18,120)   
0-19 34(6.2) 64 (16.0) 81(7.8) 179(9.0) 351(29.2) 161(25.8) 175(19.4) 687(25.2) 
< 0.00001 
19-60 98(17.7) 87(21.7) 188(18.1) 373(18.7) 283 (23.5) 189(30.3) 263(21.2) 735 (27.0) 
60-120 173(31.4) 117(29.2) 342(33.0) 632(31.8) 226 (18.8) 147(23.6) 175(19.4) 548(20.0) 
120-180 149(27.0) 83(20.8) 288(27.7) 520(26.1) 185 (15.3) 68(11.0) 152(16.9) 405(14.8) 
180-228 98(17.7) 49(12.3) 139(13.4) 286(14.4) 160 (13.2) 58(9.3) 136 (15.1) 354(13.0) 
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Education level 
None 82(14.9) 106(26.5) 236(22.7) 424(21.3) 495(41.1) 309(49.6) 319(35.4) 1123(41.2) 
 < 0.00001 
Nursery 46(8.3) 40(10.0) 52(5.0) 138(7.0) 127(10.5) 51(8.2) 123(13.6) 301(11.0) 
Primary 239(43.3) 172(43.0) 509(49.0) 920(46.2) 275(22.8) 182(29.2) 254(28.2) 711(26.1) 
Secondary/high 
school 185(35.5) 82(20.5) 241(22.2) 508(25.5) 308(25.6) 81(13.0) 205(22.8) 594(21.8) 
Identified for HIV testing through or brought to the hospital by 
Father 136(24.6) 88(22.0) 270(26.0) 494(24.9) 118 (9.8) 
130 
(20.9) 104 (11.5) 352 (12.9) 
 < 0.00001 Mother 416(75.4) 312(78.0) 768(74.0) 1496(75.1) 817 (67.8) 
368 
(59.1) 557 (61.8) 
1742 
(63.8) 
Grand-father 0(0.0) 0(0.0) 0(0.0) 0(0.0) 1 (0.1) 4 (0.6) 5(0.6) 10 (0.4) 
Grand-mother 0(0.0) 0(0.0) 0(0.0) 0(0.0) 71 (5.9) 50 (80.0) 68 (7.6) 189 (6.9) 
Others 0(0.0) 0(0.0) 0(0.0) 0(0.0) 198 (16.4) 71 (11.4) 167 (18.5) 436 (16.0) 
Mother attended ANC during pregnancy 
No N/A** 41(10.2) 6(0.6) 47(3.3) N/A 23(3.7) 4(0.5) 27(1.8) 
 < 0.00001 Yes N/A 359(89.8) 1032(99.4) 1391(96.7) N/A 552(88.6) 895(99.3) 1447(94.9) 
Unknown N/A 0(0.0) 0(0.0) 0(0.0) N/A 48(7.7) 2(0.2) 50(3.3) 
Place of birth 
Health facility N/A 296(74.0) 1006(96.9) 1302(90.5) N/A 498(79.9) 891(98.9) 1389(91.1) 
<0.00001 Home N/A 104(26.0) 32(3.1) 136(9.5) N/A 100(16.1) 7(0.8) 107(7.0) 
Unknown N/A 0(0.0) 0(0.0) 0(0.0) N/A 25(4.0) 3(0.3) 28(1.9) 
Mother received ARVs during pregnancy (only tPTIC) 
No 381(69.0) 267(66.7) 692(66.7) 1340(67.3) 
  
Yes 136(24.6) 118(29.5) 332(32.0) 586(29.4) 
Unknown 35(6.4) 15(3.8) 14(1.3) 64(3.2) 
*Data not collected for this site;  ** P value for "Total" tPITC vs bPITC 
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 Most children had never tested for HIV before with a significantly higher proportion in the bPITC group (64.3% vs 77.4%, 
p<0.00001). Even though most children’s fathers were alive, the proportion of paternal orphans was significantly higher in the tPTIC 
group than in the bPTIC (22.2% vs 5.6%, p<0.00001) and fewer maternal orphans was observed in both groups (tPITC vs bPITC: 
1.8% vs 2.3%). The large majority (96.1%) of children in the tPITC group were recruited through their parents on ART, follow by 
parents from PMTCT (1.02%) and VCT (0.3%). In the tPITC group, the large majority (88.7%) of parents preferred their children to be 
tested in the hospital and most (82.8%) children were finally tested in the hospital (Table 4.5).  
Table 4.5: HIV history of children in the tPITC and bPITC groups 
Characteristics 
 tPITC bPITC   
Limbe 
Abong-
Mbang Ndop Total Limbe 
Abong-
Mbang Ndop Total 
n (%) n(%) n(%) N(%) n(%) n(%) n(%) N(%) P* 
                  
Child ever tested for HIV before 
No 341(61.8) 356(89.0) 583(56.2) 1280(64.3) 935(77.6) 531(85.2) 646(71.7)) 2112(77.4) 
 <0.00001 Yes 199(36.0) 39(9.7) 453(43.6) 691(34.7) 200(16.6) 58(9.3) 244(27.0) 502(18.4) 
Unknown 12(2.2) 5(1.3) 2(0.2) 19(1.0) 70(5.8) 34(5.5) 11(1.3) 115 (4.2) 
HIV status of the child 
Negative 194(35.1) 38(9.5) 448(43.2) 680 (34.2) 172(14.2) 58(9.3) 241(26.8) 471(17.2) 
 <0.00001 Positive 
0(0.0) 0(0.0) 0(0) 0(0.0) 7(0.6) 0(0.0) 1(0.1) 8(0.3) 
Unknown 
358(64.9) 362(90.5) 590(56.8) 1310(65.8) 
1026(85.2) 565(9.7) 659(73.1) 
2250 
(82.4) 
Child's mother alive 
Yes 544(98.5) 396(99.0) 1016(97.9) 1956(98.2) 1177(97.7) 606(97.3) 883(98.0) 2666(97.7) 
0.15143 
No 8(1.5) 4(1.0) 22(2.1) 34(1.8) 28(2.3) 17(2.7) 18(2.0) 63(2.3) 
Mother's HIV status (only tPITC)  
Negative 31(5.6) 15(3.8) 104(10.0) 150(7.6)   
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Positive 463(83.9) 355(88.7) 894(86.1) 1712(86.0) 
Unknown 58(10.5) 30(7.5) 40(3.9) 128(6.4) 
Mother on 
ARVs drugs 
(only tPITC)         
Yes 
458 
(83.0) 
331 
(82.7) 881 (84.9) 
1670 
(84.0) 
No 53 (9.6) 39 (9.8) 115 (11.1) 207 (10.4) 
Unknown 41 (7.4) 30 (7.5) 42 (4.0) 113 (4.6) 
Child's father alive 
Yes 450(81.5) 336(84.0) 743(71.6) 1529(77.8) 1138(94.4) 590(94.7) 849(94.2) 2577(94.4) 
<0.00001 
No 102(18.5) 64(16.0) 295(28.4) 461(22.2) 67(5.6) 33(5.3) 52(5.8) 152(5.6) 
Father's HIV status (only tPITC) 
Negative 
121 
(22.0) 49 (12.2) 181 (17.4) 351(17.6) 
  
Positive 
220 
(39.8) 
174 
(43.5) 588 (56.6) 982 (49.3) 
Unknown 211(38.2) 
177 
(44.3) 269 (26.0) 657(33.1) 
Father on 
ARVs drugs 
(only tPITC)         
Yes 
201 
(36.4) 
143 
(35.7) 505 (48.6) 849(42.6) 
No 
136 
(24.6) 23 (5.8) 73 (7.0) 232(11.7) 
Unknown 215(39.0) 
234 
(58.5) 460 (44.4) 909(45.7) 
*Data not collected for this site;  ** P value for "Total" tPITC vs bPITC 
54 
 
IV.4. Acceptability, feasibility and effectiveness of PITC 
IV.4.1. Acceptability  
The ASPA study offered enrolment to 3699 parents including 1240 and 2459 
respectively in the tPITC and bPITC group. Among these parents, 99.7% (1236/1240) 
and 98.8% (2430/2459) (p=0.0005) respectively in the tPITC and bPITC group accepted 
to have their children tested for HIV. The acceptability was high across all the sites and 
in both groups: in the tPITC it was respectively 100%, 99.7% and 99.5% in Limbe, Abong-
Mbang and Ndop. In the bPITC it was respectively 99.2%, 99.3% and 98.0% in the same 
order.  In both groups, the acceptance of HIV testing among children was 100% (Table 
4.6). 
IV.4.2. Feasibility 
  Through consenting parents, the study enrolled 4719 children eligible for HIV 
testing, including 1990 in the tPITC and 2729 in the bPITC group. Among these children, 
the study was able to test 57.6% (1129/1990) and 90.3% (2465/2729) of them 
respectively in the tPITC and bPITC group. This difference was statistically significant 
(p<0.0001). In the tPITC group, the feasibility was highest (88.0%) in the Abong-Mbang 
District Hospital as compared to the Limbe Regional Hospital (54.3%, p < 0.0001) and 
the Ndop District Hospital (46.0%, p<0.0001). Likewise, in   the bPITC group, this outcome  
was still highest   in Abong-Mbang District Hospital (99.4%), followed by Ndop District 
Hospital (99.3%) and Limbe Regional Hospital (78.9%) (Table 4.6).   
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Table 4.6: Implementation outcome of tPITC and bPITC in 3 health facilities in Cameroon, ASPA Study 
 
  
tPITC 
 
  
  
 
bPITC 
 
 
 
  
Limbe 
Abong 
Mbang 
Ndop Total   Limbe 
Abong-
Mbang 
Ndop Total   
N(%) N(%) N(%) N(%)   N(%) N(%) N(%) N(%)   
Indicators                     
Parents offered 
enrolment     
327 345 568 1240  1021 579 859 2459 3699 
Parents who 
refused 
enrollment   
0 1 3 4  8 4 17 29 33 
 Parents 
enrolled   
327 344 565 1236  1013 575 842 2430 3666 
Children and 
adolescents 
offered 
enrolment     
552 400 1038 1990  1205 623 901 2729 4719 
Children and 
adolescents 
0 0 0 0   0 0 0 0 0 
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who refused to 
enrolled 
Children and 
adolescents 
enrolled   
552 400 1038 1990   1205 623 901 2729 4719 
Children and 
adolescents 
tested for HIV in 
the community 
(only tPITC) 
43 140 15 198   N/A N/A N/A       N/A N/A 
Children and 
adolescents 
tested for HIV in 
the hospital 
257 212 462 
 
 
931 
 
 
  951 619 895 2465 3396 
Children tested 
for HIV (both 
community and 
hospital) 
300 352 477 1129   951 619 895 2465 3594 
Children and 
adolescents 
tested HIV+ in 
the community 
0 1 0 1       N/A 
         
N/A 
     N/A      N/A N/A 
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Children and 
adolescents 
tested HIV+ in 
the hospital 
5 13 21 39   14 21 5 40 79 
Children and 
adolescents 
tested HIV+ 
(total HIV 
testing) 
5 14 21 40   14 21 5 40 80 
Children and 
adolescents 
initiated on ART 
1 13 20 34   3 16 2 21 55 
Outcome (%)         %CI         %CI P 
Acceptability 100.0% 99.7% 99.5% 99.7% (99.5-100) 99.2% 99.3% 98.0% 98.8% (98.3,99.2) 0.0005 
Feasibility 54.3% 88.0% 46.0% 56.7% (54.3,58.5) 78.9% 99.4% 99.3% 90.3% (89.2,91.4) <0.00001 
Case detection 1.7% 4.0% 4.4% 3.5% (2.3,4.4) 1.5% 3.4% 0.6% 1.6% (1.1,2.1) 0.0008 
Linkage 20.0% 85.7% 95.2% 82.5% (70.7,94.3) 21.4% 76.2% 40.0% 52.5% (37.0,67.9) 0.0018 
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IV.4.3. Effectiveness: case detection, case detection earliness and 
linkage 
The study tested a total of 3 594 children and adolescents; 1129 and 2465 
respectively in the tPITC and bPITC group. The prevalence (case detection or yield) of 
HIV among children was (3.5%, CI:2.3-4.4) and (1.6%, CI:1.1-2.1) respectively in the 
tPITC and bPITC group. This difference was statistically significant (p= 0.0008) (Table 
4.6). This translates to a relative risk (RR) of 2.2, indicating that the probability of 
identifying a new pediatric HIV case through the tPITC strategy is 2 times as high as  in   
the bPITC strategy.    In other words, 29 and 62 children have to be tested to identify one 
new case with the implementation of the targeted and blanket PITC strategy respectively. 
In the same line, 31 and 61 parents have to be counselled in order to identify 1 (one) case 
of HIV infection among children. However, from an intention to test (ITT) perspective, the 
case detection would be 2.0%(40/1990) in the tPITC against 1.5%(40/2729) in the bPITC. 
Hence, tPITC would be 1.43 fold as effective as bPITC.  
In the tPITC group, 18% (198/1129) of children were tested in the community and 
82% (931/1129) in the hospital and, 0.5% (1/198) of children tested in the community 
were HIV positive while this HIV positivity was 4% (39/931) among children tested in the 
hospital. This difference was statistically significant (p= 0.0299). In the tPITC group, the  
age of HIV positive children varied from 9 to 228 months with a median age of 96 months 
( 8 years) while in the bPITC, the age of HIV positive cases ranged from 2 to 228 months 
with a median of 48 months (4 years). Among all HIV positive cases identified in both 
groups (tPITC + bPITC), 78.7% (63/80) were below 15 years and only 11.2% (9/80) were 
below the age of 18 months.    
The majority (84.8%) of cases in the tPITC group were diagnosed at WHO stage 
1 while in the bPITC group, the majority of cases (39.2%)   were diagnosed at WHO stage 
3.   This difference was statistically significant (p=0.0001) (Table 4.7).  
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Table 4.7: WHO clinical staging among HIV positive children in tPITC and bPITC groups 
WHO 
staging      
tPITC bPITC 
Limbe 
Abong-
Mbang 
Ndop Total Limbe 
Abong-
Mbang 
Ndop Total 
P 
n(%) n(%) n(%) N(%) n(%) n(%) n(%) N(%) 
 Stage 1 1(50.0) 8(72.7) 
19(95.
0) 
28 
(84.8) 
1(20) 3(18.8) 1(50.0) 5(21.7) 
0.0001  Stage 2 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0) 8(50.0) 0(0) 8(34.8) 
 Stage 3 1(50.0) 3(27.3) 1(5.0) 5(15.2) 4(80) 4(25.0) 1(50.0) 9(39.2) 
 Stage 4 0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0) 1(6.2) 0(0.0) 1(4.3) 
 
In the tPITC group, 82.5% of children newly diagnosed with HIV were linked to 
care as compared to 52.5% in the bPITC group. This difference was statistically 
significant (p= 0.0018  ) (Table 4.6).  
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 IV.5. Combined effectiveness of both tPITC and bPITC  
 
IV.5.1. Outcome of targeted provider-initiated-testing and counselling (tPITC) 
During the 6 months of the implementation of the ASPA project in the 3 hospitals, 
2829 eligible children for HIV testing were identified at the HIV treatment center through 
their parents in HIV care (tPITC group). Of these children, 1163 tested for HIV, 64 
tested HIV positive and 35 enrolled on ART. There was no data to compare these 
outcomes before the introduction of the ASPA project and this because the tPITC 
strategy was not consistently practiced and monitored in respective hospitals (Table 
4.8).  
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Table 4.8: The effect of the implementation of both tPITC and bPITC in three hospitals in Cameroon 
Indicators Before ASPA After ASPA     
M1 M2 M3 M4 M5 M6 Total Mean M1 M2 M3 M4 M5 M6 Total Mean P Progression   
Number of children identified for HIV testing 
through HIV+ parents (tPITC) 
0 0 0 0 0 0 0 0 563 681 578 352 388 267 282
9 
471.5     
Number of children seen at the outpatient 
department (bPITC) 
87
8 
80
4 
99
0 
106
6 
113
8 
101
5 
5891 981.
8 
899 881 656 573 765 869 464
3 
773.8   -21.2% 
Number of children eligible for HIV testing in 
the hospital (tPITC+bPITC) 
87
8 
80
4 
99
0 
106
6 
113
8 
101
5 
5891 981.
8 
146
2 
156
2 
123
4 
925 115
3 
113
6 
747
2 
1245.3   26.8% 
Number of children tested for HIV through 
tPITC 
0 0 0 0 0 0 0 0 166 246 213 145 179 214 116
3 
193.8     
Number of children tested for HIV through 
bPITC 
12
2 
12
1 
34
2 
259 254 240 1338 223.
0 
384 364 301 327 347 367 209
0 
348.3 <0.0001 56.2% 
Number of children tested for HIV in the 
hospital (tPITC+bPITC) 
12
2 
12
1 
34
2 
259 254 240 1338 223.
0 
550 610 514 472 526 581 325
3 
542.2 <0.0001 143.1% 
Number of children tested HIV+ through 
tPITC (case detection) 
0 0 0 0 0 0 0 0 17 13 16 5 6 7 64 10.7     
Number of children tested HIV+ through 
bPITC (case detection) 
9 7 8 18 7 14 63 10.5 18 10 4 9 8 9 58 9.7 < 
0.0001 
-7.9% 
Number of children tested HIV+ in hospital 
(tPITC+bPITC) 
9 7 8 18 7 14 63 10.5 35 23 20 14 14 16 122 20.3 <0.0001 93.7% 
Number of children enrolled on ART 
through tPITC 
0 0 0 0 0 0 0 0 11 5 8 3 5 3 35 5.8     
Number of children enrolled on ART 
through bPITC 
10 5 8 11 1 9 44 7.3 7 9 3 8 5 6 38 6.3 0.1368 -13.6% 
Number of children enrolled on ART in the 
hospital (tPITC+bPITC) 
10 5 8 11 1 9 44 7.3 18 14 11 11 10 9 73 12.2 < 
0.0001 
65.9% 
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IV.5.2. Outcome of blanket provider-initiated-testing and counselling (bPITC) 
During the study period, 5891 and 4643 children were seen for external 
consultations at the outpatient department (bTPIC group) respectively before and after 
the introduction of the ASPA project. The mean number of children tested for HIV per 
month was 223.0 and 348.3 respectively before and after the intervention. This difference 
was statistically significant (p<0.0001). The mean number of HIV cases detected per 
month among children was 10.5 and 9.6 before and after the project. The difference was 
statistically significant (p<0.00001). The mean number of HIV positive children enrolled 
on ART per month was 7.3 and 6.3 respectively before and after the project. The 
difference was not statistically significant (p=0.1368) (Table 4.8).  
 
 IV.5.3. Outcome of the concurrent implementation of tPITC and bPITC   
During the implementation period of both tPITC and bPITC strategies, 7472 
eligible children were identified for HIV testing in the 3 hospitals (2829 and 4643 children 
respectively from tPITC and bPITC group). This represents a 26% increase as compared 
to the 5891 children seen at the outpatient department (OPD) of these hospitals before 
the intervention.   
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     The mean number of children tested per month for HIV was 223.0 and 542.2 respectively before and after the project.    This 
difference was statistically (p<0.0001) and represented an increase of 143% in HIV testing uptake as compared to the period prior to 
the intervention (Figure 4.5).     
 
 
 
 
 
 
 
                   
Figure 4.5: Trends in the number of children and adolescents (6weeks-19 years) tested for HIV in three hospitals in 
Cameroon 6 months before and after the ASPA project, July 2015-November 2016. 
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The mean number of HIV cases detected among children per month was 10.5 and 20.3 respectively before and after the project. 
The difference was statistically significant (p<0.0001) and represented an increase of 93.7% in HIV case detection as compared to the 
period prior to the intervention (Figure 4.6).                   
 
 
 
 
 
                            
 
                         
Figure 4.6: Trends in the number of children and adolescents ( 6 weeks-19 years) tested HIV+ in three hospitals in Cameroon 
6 months before and after the ASPA project, July 15-November 2016. 
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The mean number of children enrolled on ART per month was 7.3 and 12.2 respectively before and after the ASPA project. The difference 
was statistically significant (p=0.0001) and represented an increase of 66.0% in ART enrolment as compared to the period before the 
project (Figure 4.7).   
 
 
 
 
 
 
 
                        
Figure 4.7: Trends in number of HIV+ children and adolescents enrolled on ART in 3 hospitals in Cameroon  
6 months before and after the ASPA project, July-November 2016. 
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IV.6. Barriers to pediatric HIV testing and treatment  
IV.6.1.  Patients’ level barriers 
In the tPITC group, a subgroup of parents who initially accepted to have their 
children tested for HIV   but did not respect their promise were interviewed in order to 
determine the reasons of failure to return to the hospital with their children. The lack of 
transport fare (38.3%), children living elsewhere (25.5%) and the missing consent of the 
spouse/partner (12.7%) were the 3 main reasons of failure to return with children to the 
hospital for HIV testing (Table 4.8).  
Table 4.9: Reasons of failure to return to the hospital with children for HIV 
testing 
Reasons for not bringing children for HIV testing N % 
Children in school 6 6.9 
Children not living with me 22 25.6 
Do not want my child to know I am HIV positive 3 3.5 
Lack of time 9 10.5 
Lack of transport fare 33 38.4 
Spouse/partner opposed my decision 2 2.4 
Others* 11  12.7 
Total 86 100 
*Other reasons are presented in table 4.9 below.  
 
Other reasons mentioned by parents as hindrance for them to return to the hospital 
with their children for HIV testing include forgetfulness (36.3%), child refusal to go to the 
hospital (18.1%) and bad weather (18.18%).  
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Table 4.10: Other reasons of failure to return to the hospital with children 
for HIV testing 
 
Other reasons for not returning with children to 
the hospital for HIV testing 
N % 
Because of bad roads 1 9.1 
Because it rained seriously this morning 2 18.2 
Family related issues 1 9.1 
I forgot to bring the child 4 36.4 
Children on holidays 1 9.1 
Children refused to come 2 18.1 
Total 11 100 
 
According to parents who responded, 41.0% of them declared that they will bring 
their children for testing if transport fare is reimbursed. More than half (57.7%) declared 
that there is no external factor that can make them bring their children for HIV testing 
(Table 4.11).  
 
Table 4.11: Enablers and barriers for parents to return to the hospital with 
children for HIV testing 
What can be done for you to bring your children for HIV 
testing? 
            
N 
             % 
If spouse is properly counselled 1 1.3 
If transport fare is reimbursed 32 41.0 
Nothing (no external factor) 45 57.7% 
Total 78 100 
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The large majority of parents (74.4%) were unwilling to have their children tested 
at home by community health workers (Table 4.12).  
Table 4.12:  Parents’ willingness to have children tested at home 
Would you be willing for community health workers to come 
and test your child at home? 
N % 
No 64 74.4% 
Undecided 11 12.8% 
Yes 11 12.8% 
Total 86 100  
IV.6.2. Health care providers’ level barriers 
In the 3 study sites, we interviewed a total of 48 clinicians (doctors, nurses) to 
assess their knowledge, attitudes and practices regarding pediatric HIV care and 
treatment. Among these health care providers, 81.25 % had been trained in pediatric HIV 
testing and counselling, while 66.67% had been trained in pediatric HIV treatment. The 
majority of health care providers (72.92%) declared to have requested an HIV test to the 
last child they consulted, while 21.05% of them declared it is not necessary to request an 
HIV test to all children seen in consultation and this irrespective of the chief complaint 
(Table 4.13).  
Table 4.13: Knowledge, attitudes and practices of health care providers regarding 
pediatric HIV testing and counselling  
Knowledge, attitudes and practices  
When last did you consult a child < 19 years of age? N % 
< 3 days 23 47.92 
3-7 days 6 12.50 
>7 days 19 39.58 
Total 48 100 
Did you request for HIV test for that child? N % 
Yes 35 72.92 
No 12 25.00 
Do not remember 1 2.08% 
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Total 48 100 
Do you always request for an HIV test to all children 
during consultations? 
N % 
Yes 29 60.42% 
No 17 35.42% 
Dot not remember 2 4.17% 
Total 48 100% 
What are some of reasons you do not request HIV 
test to all children? 
N % 
HIV testing reagent not available 1 5.26% 
It is not necessary 4 21.05% 
Lack of time 2 10.53% 
Other reasons 12 63.16% 
Total 19 100% 
When last did you have a training in HIV testing and 
counselling? 
N % 
< 3 years ago 30 62.50 
> 5 years ago 3 6.25 
3-5 years ago 6 12.50 
I have never been trained 8 16.67 
I do  not remember 1 2.08 
Total 48 100 
When last did you have a training in pediatric HIV 
treatment 
N % 
< 3 years ago 26 54.17% 
> 5 years ago 3 6.25% 
3-5 years 3 6.25% 
I have never been trained 11 22.92% 
I do not remember 5 10.42% 
Total 48 100% 
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Despite a substantial 48% reduction in mother-to-child HIV transmission (MTCT) 
in the past  2 decades, an estimated 170 000 new paediatric HIV infections occurred in 
2014 (46). Moreover, due  to years of failure to prevent MTCT, as well as the success of 
ART programmes in keeping children alive, there are an estimated 2.1 million children 
below 15 years living with HIV worldwide, nearly 90% of them in sub- Saharan Africa 
(SSA)(23).  It’s estimated that every day, 410 children die from HIV across the world (47) 
and in 2013, 210,000 children and 120,000 adolescents died because of HIV/AIDS (48). 
HIV infection is the second leading cause of death among adolescents, second only to 
road traffic injuries (49). This high HIV related mortality and children and adolescents is 
mainly due to the current low pediatric ART coverage estimated. In 2016,  only 43% of 
children below 15 years of age against 53% of  adults in need were effectively on ART 
(50) and  by 2020, it is estimated that there will still be well over one million children below 
15 years old needing ART (51). Failure of PMTCT despite relatively high ANC attendance 
in most Sub-Saharan African countries will contribute significantly to the situation. For 
example in 2016 in Cameroon, the coverage of pregnant women who receive ARV for 
PMTCT was 76% (52) despite the free provision of HIV testing and ARVs drugs for 
mothers at ANC services.  
In October 2014, the UNAIDS proposed the ambitious 90-90-90 new targets to 
accelerate the HIV treatment scale-up in low-and middle income 
countries with the aim to end the AIDS epidemic by 2030 (53)). The targets, described as 
‘‘90-90-90,’’ propose that by 2020,  90% of all people living with HIV will know their HIV 
status, 90% of all people with diagnosed HIV infection will receive sustained antiretroviral 
therapy and 90% of all people receiving antiretroviral therapy will have viral suppression 
by 2020 (53). Applying the 90-90-90 paradigm to paediatrics which would require 
identifying 3.7 million infants, children and adolescents with HIV infection, treating 3.3 
million and achieving viral suppression among 3 million within the next four years (40). 
In such a context, it’s a paramount need for the global public health community to 
continue addressing the current challenges in identifying children and adolescents living 
with HIV/AIDS and providing them with long live saving antiretroviral medicines. The 
ASPA study aims at contributing to achieve this objective by assessing the comparative 
advantage of active case finding over the (passive) routine provider- initiated- testing and 
counselling in identification and linkage of children and adolescents in pediatric HIV care  
and treatment.   The assessment of active versus passive case finding strategies has 
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been published in TB control [(54), (55)].  To the best of our knowledge, this is the first 
study comparing the active versus the passive case finding in HIV control.  
 The ASPA study found that the yield of newly identified HIV cases among children 
and adolescents was twice as high with tPITC  ( index case testing or active case finding)  
as with  bPITC (routine PITC) strategy. In the tPITC group, we found a prevalence 
(yield/case detection) of 3.5%. This prevalence is also closer to the 4.0% but lower to the 
7.4% reported respectively by Saeed et al. in Malawi and Wagner et al. in Kenya in studies 
assessing the outcome of active case finding for pediatric HIV [(56), (57)].  
  This difference in the prevalence reported by Wagner et al. could be due to the 
fact that this study only enrolled children 12 years or younger while in our study children’s 
age ranged from 6 weeks-19 years. In the study of Saeed et al. the age of children tested 
for HIV ranged from 1-24 years. This age range  is similar to that of our study and may 
explained the similarity of the prevalence reported by both studies. It’s known from the 
evolution of HIV infection that only approximately 70% of children reach the age of 6 years 
(58). Therefore, lower HIV prevalence should be expected among older HIV exposed 
children as it is the case in our study likewise that of Saeed et al. 
In the bPITC group, we found a prevalence of 1.6%, similar to the 1.8% reported 
by Zoufaly et al. in a study assessing the outcome of routine PITC among children in rural 
Cameroon (59).  Our result is also closer to the 2.7% reported by Cohn et al.  in a 
systematic review and meta-analysis of pediatric HIV testing in low-middle income 
countries (60). In our study, to identify one new pediatric HIV case, 40 and 61 parents 
have to be counselled in the tPITC and bPITC group respectively and 29 and 62 children 
have to be tested in the same order.  These findings indicate that in comparison with the 
routine PITC strategy, there is less effort needed to find a new pediatric HIV case with 
the index case HIV testing approach. Hence, the index case testing strategy is more 
effective as compared to the routine PITC.  
Parents’ acceptance (acceptability of tPITC) of HIV testing for their children was  
higher in the tPITC group (99.7% vs 98.8%)   most probably because of a better HIV 
awareness level resulting to the  contact of parents in this group with HIV services. Saeed  
et al. reported a similar high acceptability (93.5%) in a study in Malawi (56). In the 
contrary, our result contrasts the 48% acceptance of HIV infected parents who accepted 
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to test their children in a referral service delivery model in Kenya reported by Wagner et 
al. (57). 
 The uptake of HIV testing (feasibility) among children  was significantly lower in 
the tPITC group (56.7% vs 90.3%, p < 0. 0001).  The prominent reasons for this low HIV 
uptake in the group in order of importance were: lack of transport fare (38.37%), children 
not living with parents (25.58%), missing consent of one parent (12.79%), lack of time to 
bring children to the hospital (10.47%); and children in school (6.98%). As per parents’ 
declarations, the lack of transport fare was the main obstacle for bringing children to the 
hospital for testing. This finding should be taken with caution if considering the variations 
observed in the HIV testing uptake percentage (feasibility of tPITC) in the 3 hospitals. 
Actually, the feasibility of tPITC was highest in Abong-District Hospital (88%), moderate 
in Limbe Regional Hospital (54. 3%) and lowest in Ndop District Hospital (46%). Through 
the humanitarian component of the ASPA project, transport reimbursed was provided to 
parents in Abong-Mbang and Ndop District Hospital. Parents were reimbursed the 
transport fare of their children when brought to the hospital for HIV testing. This support 
was not available in Limbe Regional Hospital (the funding for this support was not yet 
available when the project was lunched in Limbe). That notwithstanding, the feasibility of 
tPITC was higher in Limbe Regional Hospital in comparison to Ndop District Hospital. In 
the same line, the feasibility of tPITC was almost twice as high  in Abong-Mbang as   to 
Ndop District Hospital. This finding suggests that transport reimbursement alone cannot 
account for better outcome of HIV testing uptake among children in the tPITC group. 
Moreover, it’s observed that the Abong-Mbang District Hospital had the highest proportion 
(39.7%) of children tested in the community, followed by Limbe Regional Hospital (14.3%) 
and Ndop District Hospital (3.1%). 
 The better outcome of the feasibility of tPITC in the Abong-Mbang District Hospital 
can be explained by this higher achievement in community HIV testing for children in this 
locality. This high achievement was linked to the existence of a community distribution of 
ARVs program in Abong-Mbang District Hospital. Here, ARVs drugs are distributed in 
homes to stable patients by community health workers. This existing network was used 
by the ASPA study to reach children for HIV testing. This finding indicates the potential of 
community distribution of ARVs programs to achieve better HIV testing uptake among 
children in the tPITC group. There is need for research investigating the outcome of 
community distribution of ARVs in uptake of HIV testing among children and adolescents.   
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The low HIV uptake testing among children during the implementation of index 
case testing strategy was reported in a previous study in Kenya where only 14% of 
parents who initially consented to test children finally have their children tested (57). This 
study has provided evidence that targeting children of HIV infected parents with HIV 
testing (tPITC) is a high yield strategy. However, the optimal implementation is challenged 
by the low HIV uptake testing among children. In previous studies on pediatric HIV 
services, parents reported fearing emotional suffering for their child if tested and fears of 
a child testing positive or dying of HIV, if infected [(27), (57), (61), (62)]. Other reasons why 
parents may not want to test their children include the perception of the child being 
healthy, the uncertainty about the benefits of testing either before symptomatic illness or 
before sexual debut (61), parents feel guilt or blame regarding having possibly infected 
the child [((27), (62)], parents fear inadvertent disclosure of their own status if the child is 
tested HIV positive [(27),  (61), (63)].Thus, while designing index case testing programs 
for children and adolescents, a focus should be put on interventions/strategies to address 
the aforementioned barriers to uptake of pediatric HIV testing. Actually, in the intention to 
test (ITT)   perspective, tPITC was not twice as effective as bPITC but only 1.43 fold and 
this due to the low HIV testing uptake among children in the tPITC. This suggests that the 
superiority of tPITC over bPITC may be challenged by barriers impeding the HIV testing 
uptake among children in the context of implementation of this novel strategy. This further 
highlights the need for HIV programs to identified contextual factors and obstacles to 
tPITC uptake and address them according in order to maximize the outcome of this high 
yield strategy for pediatric and adolescents HIV cases.    
The uptake was significantly higher in the routine PITC group because children 
were already in the hospital with their parents at the time of enrolment and could be tested 
on the same day. Though the HIV testing uptake was highest (90.3%) in the bPITC, 
almost 10% of children enrolled were not finally tested. This occurred because some 
parents accepted enrolment but later  changed their decision and did not go to the 
laboratory for testing; some may have gone  to the laboratory and because of the long 
waiting time decided to leave without testing the child. Conducting the HIV testing on the 
spot or having a dedicated testing room for these children near to the counselling office 
could have reduced the missed opportunity for testing.   
In our study, pediatric HIV cases  were diagnosed earlier in the tPITC group (84.8% 
at WHO stage 1)  because this strategy tested asymptomatic children in contrast to the 
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bPITC where all children tested were already sick (34.8 % at WHO stage 2 and 39.1% at 
WHO stage 3). Our result is in line with a previous index case finding in Malawi where the 
majority (46.7%) of HIV infected children were diagnosed at WHO stage 1 (56).  
Therefore, pediatric HIV programs should prioritize the index case testing for early case 
identification as this could contribute in reducing the high mortality rate associated with 
non-treatment of pediatric HIV cases [(64), (65), ((66)]. 
Linkage to care was significantly higher in the tPITC group (82.5% vs 52.5%). This   
could be explained by the fact that the large majority of parents were already in HIV care 
(96% of children were identified through parents on ART)  and it was easier to link the 
children in HIV services. This highlights the effect  prior enrolment of parents in care could 
have in linkage of children and adolescents in HIV care and further demonstrates the 
effectiveness of the family-centered approach   in enhancing pediatric HIV linkage and 
retention in care [(67), (68),(69), (70)].  
 That notwithstanding, the variations observed in linkage   across study sites 
warrant some explanations. Actually, in the tPITC group, the linkage   in the Limbe 
Regional Hospital (20.0%) was more than 4 times as lower than in  Abong-Mbang District 
Hospital (92.9%) and Ndop District Hospital (95.2%). This can be explained by the fact 
that in Limbe Regional Hospital, there was no staff tasked to ensure linkage to care of 
children diagnosed HIV positive. Though this was the responsibility of community health 
workers of the hospital to track parents and ensure their children were linked to care, we 
later realized that this follow up was not consistently done. Hence, when starting the 
ASPA study in Abong-Mbang and Ndop District Hospital, we tasked one of the dedicated 
study staff (the Research Officer) to ensure that all children diagnosed HIV positive are 
linked to care. To achieve this, the research officer (linkage agent) was tasked to maintain 
a logbook with the names and contacts of all parents whose children were diagnosed HIV 
positive in the hospital. Through this logbook, children not linked to care could easily be 
identified and parents followed up through reminder calls. In addition to this active follow 
up, nutritional support to HIV positive children was also introduced in Abong-Mbang and 
Ndop District Hospital and this through the humanitarian component of the ASPA project. 
This support consisted in providing on monthly basis to all HIV positive children in care, 
nutritional kits (compose of milk, rice, sugar and oil) during drug refills in the hospital. 
Previous studies have demonstrated the effect of nutritional supports in improving   
retention in pediatric HIV programs (71). This intervention may have also contributed in 
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improving linkage in Abong-Mbang and Ndop District Hospital. Overall, in addition to prior 
exposure of parents in HIV care, the presence of both a linkage agent (research officer) 
and nutritional support could explain the better outcome of linkage in the tPITC group.    
 In our study, the main factor affecting linkage to care  was the lost to follow up of 
parents as some did not return  to the hospital with the child for enrollment on ART after 
diagnosis. This factor was prominent in the bPITC group where the linkage  were lowest 
(21.4%, 76% and 40% respectively for Limbe, Abong-Mbang and Ndop).  This lost to 
follow up seemed to be pronounced among parents with unknown HIV status.  We may 
have reduced it  if instead of screening the child alone, we screened both  the parent and 
the child at the same time.  There is need to investigate this hypothesis to inform 
strategies to optimize linkage among children and adolescents diagnosed HIV positive at 
the outpatient department.   
In the tPITC group, the large majority of children (96%) were recruited through their 
parents on ART. This points out the role the ART clinics may play in identification of 
pediatric HIV cases through the active case finding approach. Also in this group, only 
34.7%  of children had ever been tested for HIV despite the high acceptance   (99.7%) 
observed among parents. This finding highlights the failure of the health system  in  
offering testing opportunity to children of people living with HIV/AIDS receiving HIV 
services and this, despite the recommendation of this strategy by WHO since 2010 (26).  
The current low pediatric ART coverage in Cameroon and other Sub-Saharan Africa 
countries [(6), (50), (72)] suggests that this failure to offering HIV testing opportunity to 
children of PLHIV is not specific to Limbe Regional Hospital, Abong-Mbang and Ndop 
District Hospital, but cut across most health facilities in most countries in Africa.  There is 
need to assess health facility barriers to tPITC at country level and address them 
accordingly. Health facility barriers to routine PITC (bPITC) has been published in 
previous studies [(29), ((30), (73)] . In our study, the attitudes    of health care providers 
regarding pediatric HIV testing and counselling  was found to be suboptimal as  only 
72.9% of them requested an HIV test to the last child they consulted. Most importantly, 
21% of these care providers will not  request an   HIV test to an asymptomatic child.  
Continued education, sensitization and mentoring of health care providers are required 
to uplift the current health personnel barriers to PITC (including tPITC) and improve their 
attitudes toward pediatric HIV services.  
77 
 
The large majority (93.6 %) of parents preferred to have their children tested in the 
hospital rather than in homes. This is probably due to parents’ fear of self-disclosure, 
stigma and discrimination that the presence of the community health workers in their 
home may cause ((61)). This is further justified by the fact in this study, only 29.8% of 
parents declared to have disclosed their HIV status to all their children.  Disclosure of 
parental HIV status is known to be low worldwide and constitutes a major obstacle to the 
uptake of pediatric HIV services uptake (74). This finding should serve as a caution   when 
designing the WHO recommended HIV testing, counselling and treatment at community 
level (40). The yield of new cases identified was significantly higher among children tested 
in the hospital as compared to home-based testing, suggesting the needs to prioritize 
hospital- based HIV testing in a context of scarce resources. More so because previous 
reported that 89% of parents in HIV care will still test children at health facility level in the 
absence of home-based testing option (45).  That notwithstanding, as described above, 
considering the potential impact of using the network of community distribution of ARVs 
to reach children of PLHIV with HIV testing in homes, community HIV testing for children 
should be contextualized and implemented based on potential yield, the acceptability and 
the affordability.    
Following 6 months of implementation, the ASPA project increased HIV testing 
uptake by 143% (2.3-fold increase), almost doubled (1.93-fold increase) the case 
detection and increased by 66% the number of children and adolescents enrolled on ART 
in the 3 hospitals. These findings demonstrate that the implementation of both tPITC and 
bPITC is effective in increasing HIV testing uptake, but ineffective in HIV case detection 
and ART enrollment. This suggests that implementing both strategies at the same time 
in the same health facility may not be appropriate in low HIV prevalence context such as 
Cameroon. In fact, though effective in HIV testing uptake, bPITC was ineffective in HIV 
case detection and ART enrolment among children and adolescents. On the contrary, 
tPITC was associated with the doubling of HIV case detection, but also with a significant 
increase on ART enrolment. These findings highlight the potential of tPITC to fast track 
the expansion of HIV treatment among children and adolescents, especially in low HIV 
prevalence countries such as Cameroon. For example, in 2015 in Cameroon, among the 
39 000 children eligible for ART only 7 096 were on treatment, given a treatment gap of 
31 904 children (72). If tPITC were implemented according to the service delivery model 
of the ASPA study, and when applying the 66% progression rate every 6 months on the 
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baseline, 18 733 additional children could have been enrolled on ART every year, and 
the pediatric ART gap could be closed in this country by 2019 with the enrollment of   37 
467  children and adolescents on ART. Similar projections and results are applicable to 
other countries, especially the top 5 countries with the highest burden of pediatric HIV 
namely  Nigeria, South Africa, India, Mozambique and Kenya having nearly half of the 
1.8 million children (<15 years) living with HIV/AIDS in 2015 (75). That notwithstanding, 
the effectiveness of the implementation of both tPITC and bPITC might be different in 
higher prevalence context such as in Eastern and Southern Africa Region. There is need 
of evidence on the implementation effectiveness of both tPITC and bPITC in this Region.   
The large majority (88.9%) of cases identified in the both groups (tPITC and 
bPITC) were above the age of 18 months. This finding corroborates the UNAIDS 
Spectrum data for Cameroon and most African countries (10). 18 months being the cut-
off age for early infant diagnosis (EID) of pediatric HIV using DNA-PCR technology (39), 
our finding indicates that without requiring to DNA-PCR technology, the effective 
implementation of both targeted and blanket PITC could contribute to identify close to 
90% of all pediatric HIV cases in Cameroon and other Sub-Saharan African countries. 
This evidence should comfort the HIV program managers to investing more in rapid tests 
for pediatric HIV diagnosis. In the past decades in Cameroon and other Sub-Saharan 
African countries, the focus on pediatric HIV diagnosis has been on EID (using DNA-PCR 
technology). Despite being an effective technique in detecting HIV infection in neonates 
and infants [(76),(77)], the implementation of this technology in resource-limited settings 
is constrained by numerous  operational barriers [(78),(79),(80), (81)] and more that, the 
full and optimal implementation of this strategy will allow to detect only approximately 10-
15% of pediatric HIV cases in Cameroon and other Sub-Saharan countries. Hence, the 
need to refocus the attention to HIV rapid screening tests, cheaper and easy to use is 
evident. That notwithstanding, considering the high HIV related mortality among neonates 
and infants, the current efforts to expand the innovative approaches to EID for infants 
including point-of-care testing, SMS printers and mobile phone network to connect the 
central laboratory and health facilities should be sustained (82).  In our study, 21.3% of 
diagnosed cases were adolescents between 15-19 years, suggesting that both tPITC and 
bPITC can also contribute meaningfully in improving access to HIV care among 
adolescents, the  only age group in which AIDS-related deaths are increasing (83), and 
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where  HIV is the leading cause of deaths in Africa and the second leading cause of death 
globally (84).  
The Limbe Regional Hospital was enrolled July 2015 while the Abong-Mbang and 
Ndop District Hospitals were enrolled in June 2016. We tweaked the implementation 
strategies in these 2 additional sites from lessons learned from the first site. In particular, 
we reinforced the follow up of children diagnosed HIV + to ensure linkage (introduction of 
a linkage agent). This resulted to a higher linkage in these 2 sites as compared to the 
first. Secondly, during implementation in Abong-Mbang and Ndop District Hospital, 
provision of nutritional kits to HIV+ children in care were introduced as part of the 
humanitarian component of the ASPA project. This also contributed to enhanced linkage   
into care in these 2 sites. Hence, the results of Limbe Regional Hospital and that of 
Abong-Mbang and Ndop District Hospital are not comparable in all aspects. That 
notwithstanding, since the primary objective of the study was not to compare the outcome 
per site, but instead the outcome of both tPITC vs bPITC, the time difference in 
implementation per site does not affect the results of the study, instead this stepwise 
implementation approach was found very useful as lessons learned from the first site 
(Limbe) informed adjustments needed to have a more robust strategy for better linkage 
to care of HIV positive children. On the other hand, the fact that nor the study participants 
neither the study sites were not randomized may have introduced selection bias in the 
results. However, the study design aimed at evaluating the outcome of both strategies in 
a pragmatic context. The fact that the study was implemented in 3 hospitals located in 3 
different regions in Cameroon with an increase in sample size has increased the power 
of the study. This has increased the external validity and the generalizability of the results 
of the study. On another notes, all studies published to date and evaluating the outcome 
of targeted PITC among children   have used similar non-randomized designed [(56), 
(57)].  
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 Overall, both tPITC and bPITC are highly acceptable. The tPITC has a higher 
yield and is more suitable for early detection of pediatric HIV cases and linkage to care.  
However, the feasibility of this strategy is lower and this is due to the low HIV uptake 
testing among children and adolescents. The bPITC has a higher HIV testing uptake, but   
a lower linkage. Thus, the clinical cascade for the tPITC is challenged by the HIV testing 
uptake gap while that of the bPITC is constrained by the ART linkage gap. The ASPA 
study has demonstrated the superiority of the tPITC over the bPITC in terms of case 
detection, case detection earliness and linkage to care. However, tPITC is challenged by 
the HIV uptake of HIV testing gap (feasibility) and this points out the need to implement 
adequate strategies to overcome the parents’ level barriers impeding the optimal outcome 
of this higher yield PITC approach. Despite the superiority of tPITC, it is still important for 
care providers to offer HIV testing to sick children presenting at the outpatient 
consultations.  In fact, though the yield of bPITC may be low, providing HIV testing to 
children with clinical suspicion of HIV/AIDS should be considered to avoid missed 
opportunities in providing HIV care and treatment to sick children seen in the hospitals.  
Our study found that tPITC is a higher yield case finding and linkage strategy that   
could allow Cameroon to close the current gap in pediatric ART by 2019. Moreover, the 
implementation of tPITC should be considered to fast track the achievement of the 90-
90-90 targets among children and adolescents, especially in high burden pediatric HIV 
countries in Sub-Saharan Africa.  This study did not assess retention of children on ART 
neither viral suppression among these children. These important areas need to be 
investigated in order to provide information on the full picture of the clinical cascade of 
pediatric HIV care in Cameroon.  
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Annex 3 
 
Statement on Pre-release and Contribution 
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the protocol, raised funds for implementation, trained the study staff on data collection, 
supervised data collection, analyzed data, interpreted the results and wrote the thesis.   
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Annex 4  
QUESTIONNAIRE NO 1 : PARENTS LIVING WITH HIV/AIDS 
(Each parent/guardian should have  only  one 
form, irrespective of the number of children 
brought to the hospital) 
 
Study IDP|      |      |      |      |      I      
I        
 
1.   Full name  
2.   Residence (village/quarter)  
3.   Phone number  
The section above should be detached from this form prior to data entry  
ASPA QUESTIONNAIRE NO 1: PLWH:                                              Study IDP|      |      |      |      |      I      I      I      
4.   Age |    |    | 5.   Sex ❑           Male   ❑          Female 
6.   Education 
level 
❑ None 
❑ nursery 
❑ primary 
❑ secondary 
❑ higher level 
7.   Occupation ❑farming 
❑trading 
❑office work 
❑ student 
❑Others, specify: 
………………… 
8.   Marital status ❑Married 
❑Single 
❑Cohabitating 
❑Divorced/separated 
❑Widow/widower 
9.    Have you 
ever had TB 
❑yes 
❑no 
 
10. Are you currently on 
TB treatment? 
❑yes 
❑no 
11. Are you 
on ARV 
drugs? 
❑yes 
❑no 
12.If yes, for how long 
have you been on ARV 
drugs 
|    |    | 
13. How many 
children below 19 
years do you have? 
|    |    | 14. Have you disclose 
your HIV status to your 
children? 
❑yes, to all of them 
❑yes, to some of them, specify 
why?.......................................................... 
................ 
❑No, to none of them, specify 
why?.......................................................... 
................. 
15. How many of your children less than 19 years 
have been tested for HIV? 
If =0, go to no 19 
|    |    | 
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 Cotrimoxazole 
prophylaxis 
|    |    | 
nutritional support |    |    | 
home visits by 
community 
health workers 
|    |    | 
18. Are you receiving nutritional 
support from the 
treatment 
center? 
❑yes 
❑no 
receiving home 
visits by 
community health 
workers 
❑yes 
❑no 
a member of an 
association of 
people living 
with HIV/AIDS 
❑yes 
❑no 
are you on 
antiretroviral 
drugs (ARV) 
❑yes 
❑no 
19. How many of your children 
less than 19 years have not been 
tested for HIV? (this can be calculated 
= 13-15) 
If = 0, end of  questionnaire 
❑|    |    | 
❑  don’t have children less than 19 years that have not been tested for 
HIV 
20. Are you willing to have 
these children tested for HIV? 
❑ No 
❑ Yes (go to 22 and then enrolment form for children) 
21. Why don’t you want to 
have them tested for HIV? 
 
22. Where will you like to have your 
children tested? 
❑hospital 
❑community 
❑indifferent 
❑other, 
specify:………………………………
… 
23. How many 
children did this 
parent enrolled 
in 
the study for HIV 
testing? (this 
question should 
be answered at 
the end of the 
enrolment 
period) 
|    |    | 
  
 
16. How many of them have tested HIV positive? 
If =0, go to no 19 
|    |    | 
17. How many of your HIV 
positive children are receiving 
the following services? 
CD4 count 
monitoring 
|    |    | 
Antiretroviral drugs 
(ARVs) 
|    |    | 
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Annex 5 
QUESTIONNAIRE No 2: PARENTS/GUARDIANS ACCOMPANYING CHILDREN TO HOSPITAL 
                              (Each parent/guardian should have  only  one form, irrespective of the    
                                     number of children brought to the hospital) 
 
Study IDP|      |      |      |      |      I      I      I      I  
 
Health Facility : …………………………………………... Date of encounter:…….../ …./……. 
 
1. Full name  
2. Residence (village/quarter)  
3. Phone number  
The section above should be detached from this form prior to data entry 
ASPA QUESTIONNAIRE NO 2: Parents at OPD                                           Study IDP|      |      |      |      |      I      I      I      
4. Age |    |    | 5. Sex ❑           Male   ❑          Female 
6. Education 
level 
❑ None 
❑ nursery 
❑ primary 
❑ secondary 
❑ higher level 
7. Occupation ❑farming 
❑trading 
❑office work 
❑ student 
❑Others, specify: ………………… 
8. Marital status ❑Married 
❑Single 
❑Cohabitating 
❑Divorced/separated 
❑Widow/widower 
9. What is your 
HIV status? 
❑positive 
❑negative 
❑unknown 
10. How many children have you brought to the 
hospital today? 
|    |    | 
11. Are you willing to have these children tested for 
HIV today? 
❑yes , go to children enrollment form 
❑no if no, go to Q21 
12. Why don’t you want to have them tested for HIV 
today? 
……………………………………………………… 
   
 
Interviewed by: _                         |    |    |/|    |    |    |/|    |    |    |    |
 
 
(Name)                                       (Signature)                      (Date) 
Checked by: _                 _ |    |    |/|    |    |    |/|    |    |    |    | 
(Name)                                     (Signature)                      (Date)
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Annex 6 
QUESTIONNAIRE No 3: ENROLMENT FORM FOR CHILDREN BORN TO HIV 
POSITIVE PARENT(S) 
(Each child should have a separate 
form) 
 
Health Facility:………………………. Date of encounter:…….../ …./……. 
 
Child’ full names: …………………………………………………………………………………………… 
 
Study IDC|      |      |      |      |      I      I      I      I 
Parent’ details 
Full names  
Phone number  
Residence  
The section above should be detached from this form prior to data entry 
 
ASPA QUESTIONNAIRE NO 2: Children of PLWH       Study IDP|      |      |      |      |      I      I      I      
A.  Socio-demographic and HIV status of the child 
 
1.   Age |    |    | 2.   Sex ❑     Male   ❑          Female 
3.   Identify for HIV 
testing through 
❑Mother 
❑Father 
  
4.   Education level ❑   none 
❑   nursery 
❑   primary 
❑   secondary 
❑   higher level 
5. Did the mother 
attended antenatal 
consultations (ANC) 
during the pregnancy of 
this child? 
❑Yes 
❑No 
❑Unknown 
6.  Where was the 
child born?  
 Hospital 
 Home 
 Unkknown 
 
  
7. Was the 
mother 
received ARVs 
(PMTCT) drugs 
during 
pregnancy? 
 Yes 
 No 
 Unknown 
8.  Has the child 
ever 
tested for HIV? 
❑   yes ❑   no (go to 9) 
❑   unknown (go to 9) 
9.    What is 
the HIV 
status of the 
child? 
❑ Positive 
 
❑   Negative 
❑   unknown 
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10. Is the child receiving 
ARVs? 
❑Yes(go to Q10) 
❑No 
11.  Why is the 
child 
not in 
care? 
 
12.  Is the 
mot
her 
alive
? 
❑   yes 
❑   no 
13. Mother’s 
education 
level 
❑   none 
❑   nursery 
❑   primary 
❑   secondary 
❑   higher level 
❑     Unknown 14. Mother’s 
occupati
on 
❑   farming 
❑   trading 
❑   office work 
❑   
others, 
specify: 
…….................
.... 
15. Mother's HIV 
status 
negative 
❑   positive 
❑   unknown 
16. Is 
mothe
r on 
ART? 
❑ yes 
❑ no 
❑ unknown 
17.  Is the 
father 
alive? 
❑   yes 
❑   no 
18. 
Father’
s 
educat
ion 
lev
el 
❑   None 
❑   nursery 
❑   primary 
❑   secondary 
❑   higher level 
❑     unknown 
19. Father’s 
occupatio
n 
❑   farming 
❑   trading 
❑   office work 
❑   Others,specify: 
………………… 
20. Father’s 
HIV 
status 
Negative 
❑   Positive 
❑   unknown 
21. Is father 
on 
ART? 
❑ yes 
❑ no 
❑ unknown 
  
22. Mode of 
recruitment 
(parents from) 
 
❑ ARVs 
❑ VCT 
❑ PTMCT 
❑ TB unit 
❑ LTF 
 Others….. 
 
23. Did the mother take 
ARVs drugs during 
the pregnancy of this 
child? 
❑   yes 
❑   no 
❑   unknown 
24.   
Preferred 
site for HIV 
testing? 
❑   Hospital 
❑   Community 
❑    Indifferent 
25. Actual site for HIV 
testing? 
❑   Hospital 
❑   community 
26. 1
st 
rapid 
HIV 
test 
result 
❑   Negative 
❑   Positive 
❑Indeterminate 
27. 2
nd   
rapid HIV test 
result 
❑Negative 
❑Positive 
❑Indeterminate 
28. PCR testing 
(if child <18 months) 
❑Negative 
❑Positive❑ 
29.  Final HIV 
results 
❑Negative 
❑Positive 
❑Indeterminate 
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B. ART ELIGIBILITY ASSESSMENT AND LINKAGE TO CARE (only for HIV+ children) 
 
 
 
 
30. Clinical 
Assessment 
 
 
Weight:           .    (kg) 
Height:          .    (cm) 
Head Circumference:          .    (cm) 
WHO Staging: 
❑  Stage 1 ❑  Stage 2 
❑  Stage 3 ❑  Stage 4 
 
 
 
 
31.Laboratory 
Assessment 
 
 
 
Hb (g/dl):           .     
TLC:                   
CD4:             
%CD4:             
 
 
31. Immunological Classification: 
❑  No evidence of suppression (%CD4≥25) 
❑  Evidence of moderate suppression (15≤%CD4≤24) 
❑ Severe suppression (%CD4<15) 
 
 
32. Eligible to ART 
 
❑ No(go to Q31) 
❑ Yes 
 
33. ART regimen 
prescribed 
❑  NVP-based 
❑  EFV-based 
❑  PI-based 
 
34. Registration in 
pre-ART 
register 
 
 
❑  Yes 
❑ No 
35. specify the 
reasons for the 
non registration in 
pre-ART register 
❑  Lost to follow up 
❑  No register 
❑  Others, specify: ………...... 
 
36. Cotrimoxazole 
prescribed 
❑   yes 
❑   no, specify reasons: ………............................................. 
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Annex 7: 
                              QUESTIONNAIRE No 4: ENROLMENT FORM FOR CHILDREN SEEN 
AT THE OUTPATIENTS DEPARTMENT 
(Each child should have a separate form) 
 
   
Child’ full names: ……………………………………………………………………………………….... 
Study IDC|      |      |      |      |      I      I      I      I 
 
Parent’ details 
Full names  
Phone number  
Residence  
The section above should be detached from this form prior to data entry 
 
ASPA QUESTIONNAIRE NO 2: Children of PLWH                       Study IDP|      |      |      |      |      I      I      I      
1.   Age |    |    | 2.   Sex ❑     Male   ❑          Female 
3.   Brought to the 
hospital by 
❑Mother 
❑Father 
❑Grand-mother 
❑Grand-father 
❑Others, specify: ………................................................ 
4.   Education level ❑   none 
❑   nursery 
❑   primary 
❑   secondary 
❑   higher level 
5. Did the mother 
attended antenatal 
consultations (ANC) 
during the 
pregnancy of this 
child? 
       ❑Yes 
❑No 
❑Unknown 
 6. Where was the 
child born? 
  
 ❑ Hospital 
 ❑ Home 
 ❑ Unknown 
 
 
7.           Has the child ever 
tested for HIV? 
❑   yes 
❑   no (go to no 7) 
❑   unknown (go to no 7) 
8.    What is the HIV 
status of the child? 
 
 
❑   negative (go to 
Q9) 
❑    positive 
❑   unknown 
9.  If positive, is the 
child on ARVs 
❑ Yes ( go to Q9) 
❑ No 
10.  Why is the 
child not on 
ART 
 
11.   Is the mother alive? ❑   yes 
❑   no 
12. Mother’s 
education 
level 
❑   none 
❑   nursery 
❑   primary 
❑   secondary 
❑   higher level 
❑     Unknown 
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13. Mother’s occupation ❑   farming 
❑   trading 
❑   office work 
❑   Others, 
specify: 
…………………... 
14. Is the 
father 
alive? 
❑   yes 
❑   no 
15. Father’s education level ❑   None 
❑   nursery 
❑   primary 
❑   secondary 
❑   higher level 
❑     unknown 
16. Father’s 
occupatio 
n 
❑   farming 
❑   trading 
❑   office work 
❑   Others, specify: 
……………………………… 
17. 1
st 
rapid HIV test result ❑   Negative 
❑   Positive 
❑   Indeterminate 
18. 2
nd   
rapid 
HIV test 
result 
❑Negative 
❑Positive 
❑Indeterminate 
19. PCR (if 
child 
<18 
months) 
❑Negative 
❑Positive 
20. Final HIV status ❑   Negative (stop here) 
❑   Positive 
❑   Indeterminate 
 
 B. ART ELIGIBILITY ASSESSMENT AND LINKAGE TO CARE (only for HIV+ children) 
21. Clinical Assessment Weight:           .    (kg) 
Height:          .    (cm) 
Head Circumference:          .    (cm) 
WHO Staging: 
❑  Stage 1 ❑  Stage 2 
❑  Stage 3 ❑  Stage 4 
22.Laboratory 
Assessment 
Hb (g/dl):          .   
TLC:                   
CD4:             
%CD4:             
23. Immunological Classification: ❑  No evidence of suppression (%CD4≥25) 
❑  Evidence of moderate suppression (15≤%CD4≤25) 
❑ Severe suppression (%CD4<15) 
24. Eligible to ART ❑ No(go to Q26) 
❑ Yes 
25. ART regimen 
prescribed 
❑  NVP-based 
❑  EFV-based 
❑  PI-based 
26. Registration in 
pre-ART 
register 
 
 
❑  Yes 
❑ No 
27. specify the 
reasons for the 
non registration in 
pre-ART register 
❑  Lost to follow up 
❑  No register 
❑  Others, specify: ………...... 
28. Cotrimoxazole 
prescribed 
❑   yes 
❑   no, specify reasons: ………............................................. 
 
   
Interviewed by: |    |    |/|    |    |    |/|    |    |    |    | 
 
(Name)                                       (Signature)                      (Date)
Checked by: _               |    |__|/|    |    |    |/|    |    |    |    | 
(Name)                                     (Signature)                      (Date
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                                             Annex 8:         ASPA Study: Routine Data Form 
Pediatric consultations, testing, care and treatment 
Health Facility:………………………………………………………… 
  Jan Feb March April May June July Aug Sept Oct Nov Dec Total 
Consultation 
at OPD 
2014              
2015              
Testing of 
children in 
the lab 
2014              
2015              
Children 
tested HIV+   
2014              
2015              
HIV+ 
children 
linked to 
care 
2014              
2015              
HIV+ 
children 
initiated on 
ART 
2014              
2015              
Source: Registers: OPD Consultations, Laboratory, Pre-ART and ART 
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Annex 9 
QUESTIONNAIRE-SURVEY 
PARENTS LIVING WITH HIV/AIDS QUESTIONNAIRE 
Study IDP|___|___|___|___| 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. What is the travel time in a vehicle 
from your home to the hospital?     
 
❑<30 min        ❑30min-60min   ❑>60min 
2. What are the reasons for not 
bringing your child to the hospital for 
HIV testing? 
❑ Lack of transport money  
❑ Lack of time  
❑ Children in school  
❑ Children not living with me  
❑ Spouse/partner opposed my decision  
❑ Do not want my child to know I am HIV 
positive   
❑ Child too small  
❑ 
Others:…………………................................. 
 
3. If applicable, what can be done for you to bring your child in the hospital for HIV 
testing?  
4. Will you be willing for 
community health 
workers to come and test 
your child at home?  
❑Yes 
❑No   
 Undecided  
  I have to ask my spouse/partner 
5. Have disclose your status 
to your spouse/partner  
Yes 
No 
Do not remember 
Choose not to anwser 
  
107 
 
Annex 10 
QUESTIONNAIRE-SURVEY 
HEALTHCARE PROVIDERS INVOLVED IN CONSULTATIONS OF CHILDREN 
Study IDCP|___|___|___|___| 
1.When last did you consult a child aged 0-19 
years? 
 
❑3days    ❑3days-7days  
❑>7days 
2.Did you request an HIV for that child?   
❑  Yes 
❑  No 
❑  Do not remember 
  
 
1. What are some of the reasons you do at times request for HIV test for children 
with unknown HIV status?    
2. When was your last training in HIV testing and counselling? 
 
❑  <3years     ❑3 years-5years   ❑>5 years 
❑ I do not remember 
❑  I have never been trained 
 
3. Can you request an HIV test for all children you see in the hospital irrespective 
of their motive of consultation? 
❑  Yes    
❑  No    
❑ Undecided 
 
4. If no to No 5, please give reasons: 
 
  
108 
 
Annex 11 
Information Notice and Informed Consent Form (English and French) 
 
INFORMATION NOTICE 
ACTIVE SEARCH FOR PAEDIATIC AIDS (ASPA) STUDY: Assessing the feasibility, 
effectiveness of the targeted versus blanket provider-initiated-testing and counselling (PITC) 
among HIV infected children and adolescents in Cameroon    
Principal Investigator: Dr Yumo Habakkuk, MD, Msc,   
 
DESCRIPTION OF THE STUDY 
Aim of the study 
The ASPA study aims at identifying the best strategy that should be used by health care workers 
to identifiy HIV infected children and enrol them to HIV treatment and care and this to reduce the 
HIV/AIDS related morbidity and mortality amongst children in our community.  
Strategy and procedures of the study 
The study will offer HIV testing to children between 6 weeks to 19 years and this will be done 
following the consent of their parents/guardians. Children to be tested will be identified either in the 
hospital during consultations with their parents/guardians or through their parents receiving HIV 
services in the hospital. Orphans identified in the community will also be tested. Children could be 
tested either in the health facility or at home and this at the convenience of the parents/guardians. 
Children tested HIV positive will have another blood tests to see if they have to start HIV treatment 
(ARVs drugs). Children already enrolled on HIV treatment will be follow up to find out how they are 
doing with their treatment.    
 
Data collection and management procedures 
The interviewer will use a questionnaire to collect information from parents and children. These 
information include socio-demographic data, willingness to test for HIV, HIV serology results, ART 
eligibility, linkage to care and treatment status, nutritional support, home-visits, time of HIV 
diagnosis and parents disclosure of HIV status. Confidentiality of this information will be 
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guaranteed at all points of data collection, management and analysis by replacing names, 
addresses or other information that can lead to patient identification during or after the study.  
Research team 
The research team is made up of doctors, nurses, pharmacy attendants, laboratory technicians, 
community health workers, social workers, data managers and statisticians. These professionals 
have received training on ethical issues around the management of people living with HIV/AIDS in 
particular, as well as the ethics of their profession in general.  
Risk associated with the study 
The study is associated with the risk of confidentially breach. To minimize this, study staff will be 
trained on HIV research ethics issues.  They will also signed the confidentially agreement form. 
Children will be exposed to the risk of pains,  
excessive bleeding and hematoma due to veins punctures. To minimize this risk blood collection 
will be performed only by trained staff.    
Benefits of the study 
Participant will benefit early access to HIV diagnosis, early enrolment in care and/or treatment for 
children with HIV-infection, information on HIV infection and adherence. In addition, the knowledge 
generated by this study will be used to strengthen  the pediatric HIV program in the Cameroon and 
beyond.    
Consent to participate or withdraw from the study 
Parents/guardians or child reserve the full rights to give their free and informed consent to 
participate or not to participate in the study or withdraw whenever they deem it necessary. They 
also have the right to obtain further information for a better understanding of the study before 
giving, withdrawing or refusing their free and informed consent. They can refuse to participate or 
withdraw from the study without justification or prejudice in regards to care and treatment provided 
to them or to the child by the hospital.   Copies of the Informed Consent Form together with this 
Information Notice will be handed over to you for your record if you accept to participate in this 
project. 
This protocol has been approved by the Cameroon National Ethics Committee (NEC). For more 
information on approval of this protocol, please contact NEC through: Tel 222762114 or email: 
cnethique_minsante@yahoo.fr 
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For any problems or difficultis encountered in relation to this study, kindly contact the following 
persons: 
5. The site coordinator through the address below 
Name of site coordinator:………………………………………………………… 
Tel:............................................................................................................................. 
Email:……………………………………………………………………………..... 
6. The Study Coordinator 
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 ACTIVE SEARCH FOR PAEDIATIC AIDS (ASPA) STUDY: Assessing the feasibility, 
effectiveness of the targeted versus blanket provider-initiated-testing and counselling (PITC) 
among HIV infected children and adolescents in Cameroon    
 
I the undersigned, ______________________________ consenting on the behalf of my child and 
this with his/her assent (when applicable) that I have read or have been explained (for those who 
cannot read), and understood the aims of the ASPA study, the procedures involved in data 
collection, management and analysis, and freely give my informed consent to participate in the 
study. I was informed about the risk involved in the study for me and my child and understand that 
the study constitutes no direct nor indirect harm to my care or that of my child, and does not in any 
way infringe on my basic human and ethical rights of beneficent, non-maleficent, autonomy, justice 
and equity. I acknowledge having received appropriate information regarding the confidentiality 
involved in the handling of my information, and that I reserve the right to withdraw my consent and 
participation in the study, whenever I so deem it necessary without any negative repercussion on 
my care and/or treatment.  I have been informed on the persons to contact in case I need further 
information or encounter any problem in the course of the study. I have received satisfactory 
answers to questions I asked in relation to this study.   
Place :……………………………………………….Date:………………………………………………… 
 
Signature:………………………...........................................................................................  
 
Principal Investigator: Dr Yumo Habakkuk, MD, Msc,   
  
 
 
 
 
                    INFORMED CONSENT FORM 
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Annex 12 
ASSENT FORM 
(for children more than 11 years old) 
 ACTIVE SEARCH FOR PAEDIATIC AIDS (ASPA) STUDY: Assessing the feasibility, 
effectiveness of the targeted versus blanket provider-initiated-testing and counselling (PITC) 
among HIV infected children and adolescents in Cameroon    
 
I the undersigned, ______________________________ affirm that I have been explained and I 
understand the aims of the ASPA study, the procedures involved in data collection, management 
and analysis, and freely give my assent to participate in the study. I was informed about the risk 
involved in the study and I understand that the study constitutes no direct nor indirect harm to my 
care or that of my child, and does not in any way infringe on my basic human and ethical rights of 
beneficent, non-maleficent, autonomy, justice and equity. I acknowledge having received 
appropriate information regarding the confidentiality involved in the handling of my information, and 
that I reserve the right to withdraw my consent and participation in the study, whenever I so deem it 
necessary without any negative repercussion on my care and/or treatment.  I have been informed 
on the persons to contact in case I need further information or encounter any problem in the course 
of the study. I have received satisfactory answers to questions I asked in relation to this study.   
Done in :……………………………………………………………………………………….. 
Date:……………………………………………………………………………………………. 
Signature:………………………....................................................................................... 
 
Principal Investigator: Dr Yumo Habakkuk, MD, Msc,   
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DESCRIPTION DE L’ETUDE 
But de l'étude : L’étude ASPA vise à identifier la meilleure stratégie devant être utilisée par les 
professionnelles de la santé afin d’identifier les enfants infectés par le VIH et les mettre sous 
traitement et ceci dans le but de réduire la morbidité et la mortalité liées liée au VIH/SIDA 
pédiatrique dans nos communautés.  
Stratégies et procédures de l'étude : L’étude offrira le dépistage du VIH à des enfants de 6 
semaines à 19 ans et ceci après le consentement de leurs parents / tuteurs. Les enfants à tester 
seront identifiés soit à l'hôpital au cours des consultations avec leurs parents / tuteurs ou à travers 
leurs parents recevant les services VIH à l'hôpital. Les orphelins identifiés dans la communauté 
seront également testés. Les enfants peuvent être testés soit au sein de l'établissement de santé 
ou à la domicile et ce, à la convenance des parents / tuteurs. Les enfants testés séropositifs à 
faree d’autres tests sanguins pour voir s’ils doivent commencer de traitement du VIH 
(médicaments ARVs). Les enfants recevant déjà les antiretroviraux seront suivi pour savoir 
comment ils vont sous traitement.  
Collecte et gestion des données : Les enquêteurs vont utiliser un questionnaire pour recueillir 
des informations auprès des parents et des enfants. Ces informations comprennent des données 
socio-démographiques, la volonté de tester les enfants pour le VIH, la sérologie VIH, l’éligibilité 
aux ARVs, l’enrolement sous traitement ARVs, le soutien nutritionnel, les visites à domicile, le 
moment du diagnostic VIH et l’annonce de la sero-positivité aux enfants. La confidentialité de ces 
informations sera garantie à tous les points de la collecte, la gestion et l'analyse des données. 
Pour ce faree, avant l’analyse, les questionnaires seront codifiées en remplaçant les noms, 
adresses ou autres informations qui peuvent conduire à l'identification du patient pendant ou 
après l'étude par un numero d’étude.  
           NOTICE D’INFORMATION AUX PARTICIPANTS  
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 Équipe de recherche : L'équipe de recherche est composée de médecins, infirmières, commis 
de pharmacie, techniciens de laboratoire, agents de santé communautaires, travailleurs sociaux, 
gestionnaires des données et les statisticiens. Ces professionnels ont reçu une formation sur les 
questions éthiques autour de la gestion des personnes vivant avec le VIH / SIDA en particulier, 
ainsi que l'éthique de leur profession en général.  
Risque lié à l'étude : L’étude est associée avec le risque de violation de la confidentielle. Pour 
minimiser ce risque, le personnel de l'étude sera formé sur les questions d'éthiques de la 
recherche sur le VIH/SIDA. Ce personnel signera également le formulaire sur la clause de 
confidentialité. Les enfants seront exposés aux risques des douleurs, des saignements excessifs 
et d’hématome lors des prelevements sanguins. Pour minimiser ce risque, les prelevements 
sanguins seront effectués uniquement par du personnel formé.  
Benefices de l’étude: Les participants de l’étude bénéficieront d’un accès précoce au diagnostic 
du VIH, l'enrolement aux soins et / ou le traitement pour les enfants infectés par le VIH, des 
informations sur l'infection à VIH et l’adherence aux traitements. En outre, les connaissances 
générées par cette étude sera utilisée pour renforcer le programme de prise en charge pédiatrique 
au Cameroun et au-delà. 
Consentement à participer ou à se retirer de l’étude: Les parents/tuteurs ou les enfants se 
reservent tous les droits de donner leur consentement libre et éclairé, de participer ou ne pas 
participer à l'étude, ou de se retirer chaque fois qu'ils le jugent nécessaire. Ils ont aussi le droit 
d'obtenir amples informations pour une meilleure compréhension de l'étude avant de donner, 
retirant ou en refuser leur consentement libre et éclairé. Ils peuvent refuser de participer ou se 
retirer de l'étude sans justification, ni préjudice sur leurs soins ou traitement à l'hôpital. Les copies 
du formulaire de consentement éclairé avec la présente notice d'information vous seront remis 
pour votre dossier si vous acceptez de participer à cette étude. Cette étude a été approuvée par le 
Comité National d'Ethique du Cameroun (CNE). Pour plus d'informations sur l'approbation de 
cette étude, vous pouvez contacter s’il vous plaît CNE par : Tel 222762114 ou par email: 
cnethique_minsante@yahoo.fr. En cas de problèmes ou de difficultés rencontrés dans le cadre de 
cette étude, bien vouloir   contacter les personnes suivantes:  
1. Le Coordinateur de site à l'adresse ci-dessous : 
2. Name du coordinateur de site :……………………Tel:...............................Email:………………………. 
3. Le Coordinateur du projet:   
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into care among HIV infected children and adolescents in Cameroon    
 
Je soussigné, ______________________________ consentant au nom de mon enfant et cela 
avec son assentiment (le cas échéant) que j’ai lu ou on m’a été expliqué (pour ceux qui ne savent 
pas lire), et que j’ai compris les objectifs, les procédures de la collecte, la gestion et l'analyse des 
données de l'étude ASPA ; donne librement mon consentement éclairé à participer à cette étude. 
J’ai été informé sur le risque lié à l'étude pour moi et mon enfant et je comprends que cette étude 
ne constitue pas un préjudice direct ou indirect à mes soins ou à ceux de mon enfant, et ne peux 
en aucune façon porter atteinte à mes droits humains et éthiques de base, d'autonomie, de justice 
et l'équité. Je reconnais avoir reçu des informations appropriées concernant la confidentialité 
impliquée dans le traitement de mes données, et que je me réserve le droit de retirer mon 
consentement et ma participation à l'étude, chaque fois que je le juge nécessaire, sans aucun 
préjudice sur mes soins et / ou le traitement. J’ai ai été informé sur les personnes à contacter au 
cas où j’aurais besoin d’amples informations ou je rencontre des problèmes dans le cadre de cette 
l'étude. J’ai reçu des réponses satisfaisantes aux questions que j’ai posées en rapport avec cette 
étude.   
Fait à:……………………………………………………………………………………………… 
Date:………………………………………………………………………………………………  
Signature:………………………...........................................................................................  
  
 
 
 
 
       FORMULAIRE DE CONSENTEMENT 
ECLAIRE 
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FORMULAIRE D’ASSENTISSMENT 
(Pour enfants de plus de 11ans) 
ACTIVE SEARCH FOR PAEDIATIC AIDS (ASPA) STUDY: Assessing the feasibility, 
effectiveness of the targeted provider-initiated-testing and counselling (PITC) and retention 
into care among HIV infected children and adolescents in Cameroon    
Je soussigné, ................................................................................................................. affirme qu’il 
m’a été expliqué  et que j’ai compris les objectifs, les procédures de la collecte, la gestion et 
l'analyse des données de l'étude ASPA ; donne librement mon assentiment  à participer à cette 
étude. J’ai été informé sur le risque lié à l'étude et je comprends que cette étude ne constitue pas 
un préjudice direct ou indirect à mes soins , et ne peux en aucune façon porter atteinte à mes 
droits humains et éthiques de base, d'autonomie, de justice et l'équité. Je reconnais avoir reçu des 
informations appropriées concernant la confidentialité impliquée dans le traitement de mes 
données, et que je me réserve le droit de retirer mon assentiment et ma participation à l'étude, 
chaque fois que je le juge nécessaire, sans aucun préjudice sur mes soins et / ou le traitement. 
J’ai ai été informé sur les personnes à contacter au cas où j’aurais besoin d’amples informations 
ou je rencontre des problèmes dans le cadre de cette l'étude. J’ai reçu des réponses 
satisfaisantes aux questions que j’ai posées en rapport avec cette étude.   
 
Fait à:…………………………………………………………………………………………… 
Date:……………………………………………………………………………………………  
Signature:……………………….......................................................................................  
Investigateur Principal: Dr Yumo Habakkuk, MD, Msc,   
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THE ASPA STUDY 
CONFIDENTIALITY AGREEMENT 
 
This confidentiality agreement is signed by all ASPA Study staff to ensure that all necessary 
administrative, technical, and physical safeguards are taken to ensure the confidentiality of 
the ASPA data project. 
  
I……………………………………………………………………………………………… 
Staff member, ASPA Study  
1.  Keep all data files in a secure location. 
2.  Use only subject IDs when entering data into the database. 
3.  Not disclose any identifying information or combination of data elements (name, contact 
information, age, sex) that might allow for identification or the deduction of a study 
participant’s identity to anyone who is not an ASPA staff member. 
4.  Not attempt to link nor permit others to link the data with individually identified records in any other 
database. In the event that I discover or am able to deduce the identity of a specific participant, I 
agree that I will not reveal that information or attempt to contact these individuals. 
By signing this confidentiality statement, I acknowledge that I will follow the procedures 
described above to protect the confidentiality of ASPA data, and understand that if I do not 
follow these procedures I may be terminated from my position, and relevant disciplinary 
measures will be taken. 
Signature                                                                          Date (mm/dd/yyyy) 
 
 
